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Abstract 
Antiretroviral therapy (ART) is an effective treatment for Human Immunodeficiency 
Virus (HIV), slowing down the progression of the disease and reducing the risk of 
onward transmission of the virus. The effectiveness of ART requires life-long, strict 
adherence to the regimen which can be difficult to achieve and maintain. Motivational 
interviewing (MI) is a goal-focused, person-centred counselling approach to 
behaviour change which has been shown to improve ART adherence. There have 
been numerous process research studies which have focused on understanding how 
and why MI works, however few have been carried out within the context of ART 
adherence. This study aims to test the relational and technical pathways of the MI 
model along with exploring constructs outlined in Self-determination Theory, as 
expressed during an MI session targeting ART adherence with 62 adults living with 
HIV. Results did not find evidence for the relational pathway as MI spirit was not 
found to be associated with either change talk or ART adherence change. The 
technical pathway was partially upheld in that there was a relationship found between 
therapist use of MI-consistent methods and client change talk, however neither were 
associated with ART adherence change. There was some tentative evidence to suggest 
that naturally occurring autonomous motivation speech might have a stronger 
relationship to ART adherence than controlled motivation speech. The research 
findings are discussed in relation to previous MI process research studies. Clinical and 
research implications are outlined along with the strengths and limitations of the 
study. 
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Chapter 1: Introduction 
Overview 
Human Immunodeficiency Virus (HIV) is a virus that attacks the body’s immune 
system. HIV is treated with medications known as antiretroviral therapy (ART). ART 
cannot cure HIV but it can slow down the progression of the disease and reduce the 
risk of onward transmission of the virus. The effectiveness of the treatment requires 
strict adherence to what are often complex medication regimens. For some people 
adherence to ART can be difficult to achieve and maintain. One behaviour change 
intervention which has been employed to try to improve ART adherence is 
Motivational Interviewing (MI). This intervention has achieved successful outcomes 
across a variety of target behaviours including drug and alcohol misuse, smoking, diet 
and exercise (Burke, Arkowitz, & Menchola, 2003; Heckman, Egleston, & Hofmann, 
2010). MI has also shown promise in improving medication adherence (Palacio et al., 
2016) including ART adherence in people living with HIV (Dillard, Zuniga, & 
Holstad, 2017; Hill & Kavookjian, 2012).      
A model of the mechanisms of change within MI sessions has been developed (Miller 
& Rose, 2009). This model proposes causal pathways through which behaviour 
change occurs linking therapist factors (training, interpersonal style, empathy 
displayed, MI techniques used), client speech during the session and behaviour 
change outcomes. This study explores the technical and relational components of this 
model within the context of targeting ART adherence in a sample of people living 
with HIV. It is a secondary analysis of data collected as part of randomised controlled 
trial (RCT) investigating MI and ART adherence (Goggin et al., 2013). This study 
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investigates if client change talk mediates the relationship between therapist use of 
MI-consistent (MICO) methods (technical component) and change in ART adherence. 
It also considers if there is a mediation effect of therapist MI spirit (relational 
component) on ART adherence through client change talk.  Finally, self-
determination theory (SDT; Deci & Ryan, 1985) is a theory of personality and 
motivation which proposes that motivation can be divided into autonomous and 
controlled motivation with autonomous motivation being more self-determined. The 
relationship between ART adherence and more fine-grained naturally occurring 
motivational speech than MI specifies (autonomous and controlled motivation) is 
explored within the context of MI sessions with HIV-positive clients. It investigates if 
there is a relationship between different types of expressed ART adherence 
motivation (autonomous and controlled) and ART adherence behaviour. 
This chapter will set out an overall context for the study by providing general 
information about HIV including ART and medication adherence. Next the 
therapeutic intervention MI will be introduced by detailing its development and what 
the approach entails. Research into the effectiveness of MI and the mechanisms by 
which it is hypothesised to work will also be presented along with information about 
SDT and where it might fit within the framework of MI. Finally, current MI process 
research within the context of HIV is discussed, including its limitations, thus leading 
to the study hypotheses.  
Human Immunodeficiency Virus 
HIV is among the leading causes of death worldwide (Lozano et al., 2012). In 2015 
there were an estimated 36.7 million people across the world living with HIV, and 1.1 
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million died of HIV-related causes (UNAIDS, 2016b). The most recent survey 
indicates that there are an estimated 1.2 million people living with HIV in the United 
States (Hall et al., 2015) with men who have sex with men (MSM) and African-
Americans being disproportionally affected (Centers for Disease Control and 
Prevention, 2015). In 2015 in the UK there were an estimated 101,200 people living 
with HIV with MSM and Black African heterosexual women and men being most 
affected (Kirwan, Chau, Brown, Gill, & Delpech, 2016). HIV is a virus which targets 
CD4 lymphocyte cells in the body to act as a host for viral replication (McCune, 
2001). These cells are essential for healthy immune function and over time their 
depletion leads to acquired immunodeficiency syndrome (AIDS), the end stage of 
HIV (Fauci, 1988). AIDS is typified by a CD4 count of <200 cells/mm3 (the CD4 
count of a healthy person who is HIV negative ranges from 500 to 1,600 cells/mm3) 
and the development of life threatening diseases or infections such as tuberculosis, 
cancer or toxoplasmosis (Klimas, Koneru, & Fletcher, 2008).  
The origins of HIV have been widely debated and has been the focus of research since 
AIDS was first recognised as a disease in 1981 (Greene, 2007). Current consensus is 
that HIV is related to the Simian Immunodeficiency Virus (SIV) which is naturally 
found in African monkeys and apes (Gao et al., 1999). This virus is thought to have 
passed to humans through hunting and eating infected primates, with the virus 
eventually adapting to and mutating in the human body to become HIV type 1 and 
type 2 (Sharp & Hahn, 2011). Research has shown that the first transmutation of SIV 
to HIV is likely to have happened around 1920 in Kinshasa, the capital of what is now 
the Democratic Republic of Congo (Faria et al., 2014). HIV is transmitted through 
contact with contaminated bodily fluid through open cuts or sores on the skin; through 
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mucous membranes in the vagina, rectum, penis or mouth; or through injection into 
the bloodstream. The most common modes of transmission include through 
unprotected sexual contact, sharing needles or syringes with infected drug users and 
from mother to infant during pregnancy, delivery or through breastfeeding (Shaw & 
Hunter, 2012). In 2015 there were an estimated 2.1 million new HIV infections 
worldwide with the largest concentration in Eastern and Southern Africa (UNAIDS, 
2016b).  
Without intervention, there are broadly four main stages of HIV infection (Fanales-
Belasio, Raimondo, Suligoi, & Buttò, 2010; World Health Organization, 2005). The 
primary infection stage usually lasts for a few weeks and is often accompanied by 
relatively mild flu-like symptoms such as fever, headache, skin rash, oral ulcers, 
diarrhoea and sore throat lasting between seven and ten days (Schacker, Collier, 
Hughes, Shea, & Corey, 1996). As these symptoms are mostly non-specific primary 
HIV infection is not usually diagnosed at this stage (Weintrob et al., 2003). Through a 
process called seroconversion the immune system responds to HIV in the body by 
developing antibodies and cytotoxic lymphocytes to fight off the virus (Kahn & 
Walker, 1998). Once seroconversion has taken place the body enters the clinically 
asymptomatic phase which for some people can last 10 to 15 years (Buchbinder, Katz, 
Hessol, O’Malley, & Holmberg, 1994). During this asymptomatic stage the body is in 
a state of persistent inflammation and the immune system is chronically activated 
resulting in the slow loss of CD4 cells, the destruction of the immune system and the 
aging process appears to be accelerated (Appay & Sauce, 2008; Ford, Puronen, & 
Sereti, 2009). The third stage is symptomatic HIV infection which is the point at 
which the immune system has begun to fail and the person develops opportunistic 
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infections and cancers such as pulmonary tuberculosis, oral candidiasis, pneumonia, 
and unexplained persistent diarrhoea or fever (World Health Organization, 2005). In 
the final stage of HIV the person has developed an opportunistic disease or cancer 
which is life-threatening such as HIV encephalopathy, Kaposi’s sarcoma, lymphoma 
or invasive cervical cancer (World Health Organization, 2005) and can be given the 
diagnosis of AIDS.  
Antiretroviral therapy 
The development of the first diagnostic HIV antibody test in 1985 (Ward et al., 1986) 
paved the way for clinical trials for HIV, with azidothymidine (AZT) being one of the 
initial drugs tested (Furman et al., 1986). AZT (a reverse transcriptase inhibitor) was 
found to be associated with improved survival for an initial period of 24 weeks and 
was approved for use in patients with advanced HIV (Fischl et al., 1987). Other 
similar drugs were developed over the next decade but in retrospect these drugs were 
highly toxic, produced limited long-term clinical benefits and held a risk of drug 
resistance (Lundgren et al., 1994; Saag et al., 1993). HIV treatment was 
revolutionised in the mid-1990s with the recognition of the importance of the quantity 
of HIV virus present in the blood or viral load (Mellors et al., 1996), the benefits of 
combined drug therapies being realised (Hammer et al., 1996) and the development of 
protease inhibitors such as saquinavir which when combined with other drugs, were 
found to produce a decrease in viral load (Gulick et al., 1997). It is recognised that 
<50 copies/ml is needed to achieve undetectable levels of HIV virus in the blood 
(UNAIDS, 2016a). Combining ART drugs is sometimes referred to as combination 
antiretroviral therapy (cART) or highly active antiretroviral therapy (HAART). Since 
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then new drug families have been developed including fusion inhibitors, co-receptor 
inhibitors, and integrase inhibitors (De Clercq, 2009). Continued progress and 
development across all classes of HIV medications has expanded the number of 
potential drug combinations available and led to a reduction in adverse effects of the 
drugs (Fauci, 2003).  
Thanks to the advances in antiretroviral therapy HIV has moved from being a 
terminal illness to a chronic disease particularly when diagnosed and treated early 
(Mitchell & Linsk, 2004). ART works by inhibiting viral replication and reducing 
viral load thereby preventing disease progression and reducing the risk of onward 
transmission (Crum et al., 2006). HIV medications serve to reduce mortality and 
improve quality of life for those living with HIV and since 2015 it is recommended 
that all people with a diagnosis of HIV take ART regardless of CD4 count or viral 
load (World Health Organization, 2016). At the time the RCT that this study derives 
its data from (Goggin et al., 2013) was conducted, ART was only recommended for 
people who were displaying clinical symptoms of HIV or had a CD4 count of ≤200 
cells/mm3, and for those who were asymptomatic, ART was to be considered on an 
individual basis with CD4 count between 200 and 350 cells/mm3 (Hammer et al., 
2006; Yeni et al., 2004).  
In the United States, Marcus et al. (2016) found that in 1996 the average life 
expectancy for a person living with HIV was 39 years, representing a gap of 44 years 
between the life expectancy of those living without HIV and by 2011 it had increased 
to 73 years – just 12 years behind HIV-negative individuals. This increase in life 
expectancy has been attributed to the developments and improvements in ART 
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treatment (Marcus et al., 2016) and early diagnosis (Nakagawa et al., 2012). 
Worldwide, there are an estimated 17 million people (46% of those living with HIV) 
prescribed ART which is a substantial increase from 7.5 million (23%) in 2010 
(UNAIDS, 2016b). In an effort to end the HIV epidemic the joint United Nations 
Programme on HIV and AIDS (UNAIDS) and collaborators have set a global target 
(90-90-90 target) aiming to diagnose, provide ART and achieve viral suppression in 
90% of all people living with HIV by 2020 (UNAIDS, 2014).  
ART adherence 
ART involves taking a combination of HIV drugs, often three or more from at least 
two different drug classes. This is known as a HIV regimen. The drugs come in 
different forms such as tablets, capsules and syrups (which are usually just for infants 
and young children) and are taken once or twice a day at a specific time and often 
with special instructions (e.g., on an empty stomach), for the rest of the person’s life. 
For some regimens, the drugs are combined in a single tablet (known as a fixed-dose 
combination) to be taken once a day (e.g., atripla) while other regimens are more 
complex and can involve having to take up to six tablets, at specific times during the 
day, some with food and some on an empty stomach (Fogarty et al., 2002). The 
effectiveness of ART depends on strict adherence to the medication regimen (de 
Olalla et al., 2002). ART requires not only dose adherence (percentage of prescribed 
doses taken) but also schedule adherence (percentage of doses taken on time) 
(Nieuwkerk et al., 2001) as it is important to maintain a continuous coverage of ART 
within the blood to minimise the risk of developing drug resistance. The World Health 
Organization (2003) define adherence to long-term medication as the extent to which 
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medication-taking behaviour corresponds to the instructions and advice given by the 
healthcare provider. Within the context of ART, adherence involves taking all doses 
at the scheduled times, following any special instructions (e.g., with or without food) 
and ensuring no other drugs are taken that might interfere with the HIV medications. 
Due to the toxicity of the drugs ART comes with both short and long-term adverse 
effects (Margolis, Heverling, Pham, & Stolbach, 2014). Common short-term adverse 
effects include bloating, nausea, abdominal pain, diarrhoea, fatigue, rash, toxicity of 
central nervous system (dizziness, nightmares and balance problems), anaemia, 
jaundice and pancreatitis (Carr & Cooper, 2000; Hawkins, 2010). One of the most 
common long-term adverse effects of ART is mitochondrial toxicity which manifests 
as myopathy (muscle disease), neuropathy (nerve damage), lipodystrophy (peripheral 
fat loss and central fat accumulation) and, hyperlactatemia and lactic acidosis 
(abnormal levels of lactate in the body) (Montessori, Press, Harris, Akagi, & 
Montaner, 2004). Other long-term adverse effects include cardiovascular events 
(increased risk of heart attack), hepatotoxicity (chemical-driven liver damage), renal 
adverse events (impaired kidney function), and distal sensory peripheral neuropathy 
(numbness or pain in the extremities) (Hawkins, 2010).  
Correct adherence to ART can suppress HIV viral load to undetectable levels in the 
blood (Montaner et al., 1998) and this reduced viral load is associated with improved 
survival (Rodger et al., 2013), prevention of perinatal transmission of the virus in 
women (Centers for Disease Control and Prevention, 2006), improved clinical 
outcomes and reduction in sexual transmission of the virus (Rodger et al., 2016). ART 
adherence is also associated with reduced hospital admissions (Paterson, 2000) and 
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improved quality of life (Mannheimer et al., 2005). Even when HIV is undetectable in 
the blood it continues to replicate in the lymphatic tissue in the body in particular the 
gut and lymph nodes (Fletcher et al., 2014) and once ART is stopped the level of HIV 
in the blood quickly rebounds (Chun, Davey, Engel, Lane, & Fauci, 1999). It has been 
found that intermittent use of ART (stopping and starting treatment depending on 
CD4 counts) is associated with decreased quality of life (Burman et al., 2008), and an 
increased risk of death and opportunistic infections (Strategies for Management of 
Antiretroviral Therapy (SMART) Study Group, 2006). This means that it is essential 
that ART is taken consistently and for life to ensure the viral load is continually 
suppressed to undetectable levels (viral suppression) to reduce the risk of replication 
and adaptation of the virus in the body. Non-adherence can result in drug-resistant 
mutations of the virus being transmitted to uninfected people who are then newly 
infected with a drug-resistant strain of the virus and thus have less effective treatment 
options available to them (Wainberg & Friedland, 1998). Consequently, adherence to 
ART medication has public health implications and achieving viral suppression in 
those receiving ART is one of the goals set out by the UNAIDS – Lancet Commission 
in their plan to end the AIDS epidemic by 2030 (Piot et al., 2015).  
Research has found that adherence rates of less than 95% are associated with the risk 
of drug-resistance which can lead to the evolution of mutant drug-resistant strains, 
progression of the disease, and an increased risk of transmission of the virus 
(Apisarnthanarak & Mundy, 2010; Bangsberg, 2006; Harrigan et al., 2005). There is 
some research to suggest that moderate adherence levels of an estimated 70 – 80% are 
adequate for viral load suppression when taking the newer HIV drugs which have 
longer half-lives and can therefore better accommodate occasional missed doses 
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(Kobin & Sheth, 2011; Nachega et al., 2007; Shuter, Sarlo, Kanmaz, Rode, & 
Zingman, 2007). However it has also been demonstrated that adherence levels of 70 – 
80% are associated with the highest risk of developing drug resistance (Bangsberg, 
Moss, & Deeks, 2004; Sethi, Celentano, Gange, Moore, & Gallant, 2003). A recent 
meta-analysis found that viral load suppression was achieved with newer 
antiretroviral drugs and adherence rates of at least 80% but that ultimately increased 
adherence was associated with improved outcomes (Bezabhe, Chalmers, Bereznicki, 
& Peterson, 2016). Consequently, patients should be advised to aim for at least 95% 
adherence but that slightly lower levels of adherence (80 – 95%) should not deter 
clinicians from prescribing ART regimens. The majority of adherence studies focus 
on percentage of doses taken and as yet there are no guidelines regarding ART 
scheduling adherence. However, it has been shown that poor scheduling adherence is 
associated with less viral load suppression (Nieuwkerk et al., 2001). In conclusion, the 
current advice is that taking ART as prescribed 100% of the time should be the goal 
of ART adherence (Marcellin, Spire, Carrieri, & Roux, 2013).  
Although ART has dramatically improved outcomes for people living with HIV, and 
the risks associated with non-adherence are substantial, adherence rates are often low.  
It is estimated that only 62% of ART users worldwide are achieving adherence rates 
of at least 90% (Ortego et al., 2011) and only 30% of ART users in the United States 
are achieving viral suppression despite the 90-90-90 targets (Bradley et al., 2014).  
Systematic reviews and meta-analyses on ART adherence rates have been carried out 
across different populations. An estimated 74% of pregnant ART users in low and 
middle income countries achieved adherence rates of over 80% (Nachega et al., 
2012). At least 70% of adolescent ART users in Asia and Africa were optimally 
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adherent in comparison to 50 – 60% adherence rates observed in Europe and North 
America (Kim, Gerver, Fidler, & Ward, 2014). ART adherence rates were estimated 
to be 38% among female sex workers across the world (Mountain et al., 2014). An 
approximate 60% ART adherence rate has been observed in drug users (Malta, 
Magnanini, Strathdee, & Bastos, 2010) and an estimated 54.6% of incarcerated ART 
users achieved adherence of at least 95% (Uthman, Oladimeji, & Nduka, 2017).  
Ickovics and Meade (2002) have developed a conceptual model of the determinants of 
ART adherence to guide research. Their model proposes that patient variables, 
treatment regimen, disease characteristics, patient-provider relationship and clinical 
setting are interrelated factors of ART adherence. Extensive research has been carried 
out to identify the factors of ART adherence through systematic reviews and meta-
analyses. Some reviews have focused on studies which explore the associations 
between potential correlates or predictors and ART adherence (Ammassari et al., 
2002; Atkinson & Petrozzino, 2009; Bock et al., 2016; Langebeek et al., 2014; Ortego 
et al., 2011), whilst others have reviewed studies using qualitative (interviews and 
focus-groups) and quantitative (self-report questionnaires and clinical interviews) 
methods to gather patient-reported information regarding barriers and facilitators of 
ART adherence (Mills et al., 2006; Shubber et al., 2016).  
Patient variables include sociodemographic factors (such as age, sex, ethnicity, 
education, socioeconomic status, sexuality, and housing status) and psychosocial 
factors (such as mental health, substance use, social support, knowledge and beliefs) 
(Ickovics & Meade, 2002).  Patient variables identified as adherence barriers in a 
systematic review of global ART adherence include; fear of disclosure, substance 
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misuse, forgetfulness, decreased quality of life and poor understanding of the benefits 
of ART (Mills et al., 2006). Facilitators of adherence were also identified and they 
include self-worth and understanding the need for strict ART adherence (Mills et al., 
2006). A recent review investigating self-reported ART adherence barriers across the 
life-span found that the most common patient variables reported were; forgetfulness; 
being away from home; depression; drug or alcohol abuse (for adults and 
adolescents); and fear of disclosure of HIV status (Shubber et al., 2016). In a meta-
analysis of correlates of ART adherence Langebeek et al (2014) found a strong effect 
for adherence self-efficacy (belief in one’s ability to adhere to ART), and medium 
effect sizes for substance use, beliefs about needing ART, symptoms of depression, 
stigma about HIV and social support.  
Adherence factors relating to treatment regimen include the type of tablets and 
number prescribed (pill burden), the complexity of the dosing schedule, any special 
instructions required, and the adverse effects experienced (Ickovics & Meade, 2002). 
Complicated regimens, the number of tablets prescribed and access to medications 
have been found to be self-reported barriers to ART adherence across high, middle 
and low income countries (Mills et al., 2006). Self-reported facilitators of ART 
adherence are having a simple regimen and experiencing positive effects of ART 
adherence (Mills et al., 2006). HIV-related symptoms, adverse side effects and 
complex regimens were found to be predictors of nonadherence (Ammassari et al., 
2002). While Langebeek et al (2014) found small effects for pill burden, being 
prescribed a protease inhibitor-containing regimen, and daily dosing frequency being 
associated with increased ART adherence.  
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Disease characteristics include the stage and duration of the disease, the presence of 
opportunistic infections and HIV-related symptoms (Ickovics & Meade, 2002). 
Adherence rates of at least 90% are associated with earlier stages of the disease 
(Ortego et al., 2011). High baseline viral load and CD4 count has been found to be 
associated with nonadherence (Atkinson & Petrozzino, 2009). Feeling sick is a 
stronger barrier to ART adherence than feeling well (Shubber et al., 2016). A 
systematic review and meta-analysis comparing baseline CD4 count and ART 
adherence has found that higher CD4 count was associated with lower chances of 
being ART adherent however the evidence is not consistent across studies and further 
research is needed before any definitive claims can be made (Bock et al., 2016). 
Patient-provider relationship factors include patient satisfaction with care received, 
perception of the clinician’s competence, how patient-centred the clinician is, level of 
positive affect expressed within the patient-provider relationship and adequacy of the 
referrals (Ickovics & Meade, 2002). Trust in and satisfaction with the HIV care 
provider were also found to be associated with ART adherence with medium effect 
sizes observed (Langebeek et al., 2014). Shared-decision making has been associated 
with increased odds of correct adherence (Atkinson & Petrozzino, 2009). 
Characteristics of the clinical setting include pleasant clinic environment, availability 
of a specialist adherence program, access to transportation and convenience of clinic 
location (Ickovics & Meade, 2002). Meta analytic research has shown that greater 
distance to the health clinic and a lack of stock were both found to be significant 
barriers to ART adherence in low and middle-income countries (Shubber et al., 2016).  
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Measuring adherence  
Medication adherence for long-term health conditions in high and middle-income 
countries around the world is estimated to be 50% with low-income countries seeing 
even lower rates of adherence (World Health Organization, 2003).  Poor medication 
adherence is associated with increased healthcare costs and hospital admissions 
(Sokol, McGuigan, Verbrugge, & Epstein, 2005), poor clinical outcomes (Cramer, 
Benedict, Muszbek, Keskinaslan, & Khan, 2008) and even death (Simpson et al., 
2006). Vrijens et al. (2012) have described the process of medication adherence or 
taking medication as prescribed, as occurring in three distinct phases: initiation, 
implementation and discontinuation. Initiation encapsulates the first time the person 
takes their prescribed medication, for example when a person takes ART for the first 
time. Implementation is the extent to which the person is following the prescribed 
instructions given by their healthcare provider such as how close the actual doses of 
ART taken is to the prescribed regimen. The final stage is discontinuation and this 
happens when the person stops taking the prescribed medication.  
Adherence can be measured in a variety of ways incorporating subjective and 
objective measures (Brown & Bussell, 2011). Subjective measures of adherence 
include patient-report diaries, clinical interviews where the clinician asks the patient 
direct questions about their adherence, and clinician or carer/family report on the 
adherence behaviour of the patient. There are also numerous patient self-report 
questionnaires and scales to measure adherence with specific measures developed for 
different health conditions and medications (Nguyen, Caze, & Cottrell, 2014). 
Subjective measures are inexpensive and easy to administer but they have some 
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limitations. Healthcare professionals often overestimate the ART adherence levels of 
their patients (Bangsberg et al., 2001) while patients have been shown to underreport 
missed doses (Norell, 1981) possibly due to a bias in recall or social desirability. 
Examples of objective adherence measures include pill counts, prescription refill data, 
drug concentration, biochemical measures, directly observed therapy and electronic 
medication devices (Osterberg & Blaschke, 2005). Pill counts involves counting the 
medications and assuming any surplus medication to the amount expected represents 
missed doses. Pill counts can be time consuming and can overestimate adherence as it 
does not account for the patient disposing of medication rather than taking it (Liu et 
al., 2001). Pharmacy refill data presumes that prescription filling corresponds to 
medication taking and is a simple yet effective way of collecting adherence data 
(Osterberg & Blaschke, 2005). Although superior to self-report (Sangeda et al., 2014), 
like pill count, pharmacy refill data does not guarantee that the medication was 
ingested by the patient and it is a less sensitive measure of adherence for medications 
such as ART where the time of dose taken is a key indicator of level of adherence 
achieved. It is often possible to test the presence of the level of the drug in the body, 
while biochemical methods involve adding a nontoxic marker to the medication and 
then tracking its levels in either blood or urine. Both methods are limited in measuring 
ART adherence as they cannot provide information on adherence patterns and are 
influenced by individual variations in metabolism, diet and other drugs taken (Lam & 
Fresco, 2015). Directly observed therapy (DOT) methods involves patients being 
observed taking their medications as prescribed. This method is expensive and carries 
the risk that patients may feign drug taking and hide the medication under their tongue 
(Farmer, 1999). The most common electronic device used is the Medication Event 
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Monitoring System (MEMS) cap. These are lids that are placed on medication bottles 
and they record the date and time that the bottle is opened. The benefit of this 
measurement tool is that it generates detailed adherence information which can help 
track patterns of non-adherence. It is limited by the fact that it is bulky and therefore 
less convenient and discrete for patients to use. It is also expensive and does not 
guarantee that the patient ingested the medication when they opened the bottle 
(Farmer, 1999).  
Electronic methods are currently recognised as the gold standard in adherence 
measurement and have even been shown to improve adherence by helping the patient 
to identify patterns in their medication taking behaviour (Vrijens, Urquhart, & White, 
2014). It has also been demonstrated that MEMS caps are mostly consistently 
associated with viral load in studies of ART adherence compared with other methods 
of measuring adherence (Farley, Hines, Musk, Ferrus, & Tepper, 2003; Müller, Bode, 
Myer, Roux, & von Steinbüchel, 2008).  
Model of ART adherence 
Psychological models have been developed to help understand the complexities 
involved in adhering correctly to prescribed medication. The Information-Motivation-
Behavioural Skills (IMB) model (Fisher, Amico, Fisher, & Harman, 2008) has been 
developed as a framework for understanding the multifaceted process of ART 
adherence and is based on the Theory of Planned Behaviour (Ajzen, 1991). This 
model proposes that adherence information and motivation are associated with 
adherence-related behavioural skills which then predicts ART adherence (Fisher et al., 
2008). Adherence in turn can lead to positive health outcomes which influence future 
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behaviour by strengthening motivation and reinforcing adherence skills. The client 
must possess accurate ART related information including the specifics of the ART 
regimen, any potential side-effects or drug interactions, and decision rules regarding 
medication adherence (Fisher et al., 2008). Adherence motivation encompasses 
personal attitudes towards ART adherence such as holding the belief that it is 
important to adhere to the medication regimen or having the attitude that non-
adherence is the wrong thing to do, and perceived social support involves the person 
feeling supported by friends and family to adhere to the ART (Fisher et al., 2008). 
Finally, behavioural skills comprise the objective ability and perceived self-efficacy 
to adhere correctly to the medication regimen (Fisher et al., 2008). The model also 
proposes factors which moderate adherence including substance misuse, chaotic home 
environments, psychological distress and limited access to services.  Several empirical 
studies have found support for the IMB model of ART adherence (Amico et al., 2009; 
Amico, Toro-Alfonso, & Fisher, 2005; Starace, Massa, Amico, & Fisher, 2006). 
ART adherence interventions 
The current global consolidated guidelines for the use of ART recommend the 
following adherence support interventions for people being prescribed ART: peer 
counsellors; reminder text messages; reminder devices; behaviour skills and 
medication adherence training; fixed-dose combinations and once-daily regimens; and 
cognitive-behavioural therapy (World Health Organization, 2016). The guidelines are 
informed by a recent systematic review and network meta-analysis (Kanters et al., 
2016, 2017). Interventions were compared to standard care which involved the care 
provider giving instructions on how to take the medication and the importance of 
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adhering to the ART (Kanters et al., 2017). Adherence interventions were found to be 
especially successful when used in combination with one another. Peer counsellors 
involve any interventions where adherence is enhanced through involving other 
people (family, friends or professionals) such as directly observed therapy, patient 
support groups or involving family or friends in adherence counselling session 
(Kanters et al., 2016). Text messaging encompasses sending a patient reminder 
messages to take their ART medication while reminder devices include calendars, 
alarms, or pagers (Kanters et al., 2017). Behaviour skills and medication adherence 
training is any intervention where the patient learns practical skills for how to manage 
their medication and is educated on the specifics of ART adherence. Kanters et al. 
(2017) used cognitive behavioural therapy as an umbrella term to include several 
psychologically-based interventions such as cognitive-behavioural therapy (CBT), 
cognitive-behavioural stress management, counselling with a trained professional and 
motivational interviewing. CBT focuses on changing unhelpful patterns of thinking 
and behaviour which may be maintaining current difficulties. Cognitive behavioural 
stress management combines aspects of CBT with stress management techniques such 
as relaxation and breathing techniques. Within the adherence literature the term 
counselling refers to both pharmacist or nurse led education and support sessions 
(adherence counselling) and supportive counselling based on psychological 
principles. Motivational interviewing (MI) is a goal focused person-centred 
counselling approach to behaviour change and will be described in more detail in the 
subsequent section.    
Motivational Interviewing  
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MI is a both a philosophical approach to counselling and a collection of therapeutic 
techniques. It developed organically through William Miller’s work with people with 
substance misuse problems. Miller (1983) recognised that ambivalence is a universal 
human experience and he viewed it as a normal process on the journey towards 
change. When faced with behaviour change we can see both reasons to change and 
reasons to maintain the status quo. MI is a way of relating to people with the aim of 
helping them to work through ambivalence and commit to behaviour change (Miller, 
1983). Miller went on to collaborate with Stephen Rollnick to further clarify and 
extend the therapeutic approach. Together they define MI as a goal-focused, person-
centred counselling style that aims to elicit and strengthen the client’s own motivation 
for behaviour change (Miller & Rollnick, 2012).   
MI is heavily influenced by the work of humanistic psychologist, Carl Rogers, and 
adopts a supportive and empathic approach towards the client. In contrast to person-
centred therapy (Rogers, 1980) MI is transparent about its goal-oriented and directive 
nature. MI is also influenced by self-perception theory (Bem, 1972) which proposes 
that people become more committed to that which they hear themselves talk about or 
defend. Applying this theory to a therapeutic context, it suggests that the more a client 
talks about their reasons for changing a behaviour the more likely it is that behaviour 
change will occur. Hence a focus of MI is to elicit the client’s own arguments for 
change or ‘change talk’ and reduce arguments for maintaining the status quo or 
‘sustain talk’ (Miller & Rollnick, 2012).  
Miller and Rollnick (2012) have divided the process of conducting MI into four main 
stages; engaging, focusing, evoking and planning. The first step is to engage the client 
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and create a strong therapeutic relationship. Once this has been achieved the therapist 
moves to focusing the client on change by developing and maintaining the direction 
of the conversation towards behaviour change. Next the therapist aims to elicit the 
client’s own arguments for behaviour change. The final stage is planning the specific 
steps that the client will take towards behaviour change. Client resistance is possible 
at any stage of the process and is understood as an indicator to the therapist that they 
need to do something different. Within psychotherapy, resistance is understood as 
unconscious or conscious ways in which the client resists or obstructs therapeutic 
change in an attempt to maintain the status quo, which is usually a safer and more 
familiar position for the client to occupy (Blatt & Erlich, 1982). The aim within MI is 
to sidestep the resistance thorough using reflective statements to show the client their 
arguments have been heard or emphasising that it is the client’s decision to change or 
not. Sidestepping resistance is advised rather than confronting it as direct 
confrontation usually just results in an escalation in resistance (Moyers & Rollnick, 
2002).  
The therapist sets the scene for eliciting change talk by embodying the ‘spirit of MI’ 
which involves adopting an accepting, compassionate and collaborative 
communication style while encouraging client autonomy and evoking motivation to 
change (Miller & Rollnick, 2012). The therapist does not take an expert position and 
instead the client is viewed as a collaborator. From an MI perspective, change is only 
possible once a person has been fully accepted for who they are. The therapist 
demonstrates this acceptance through unconditional positive regard for the client; 
accurate empathising or attempting to view the world from the client’s perspective; 
believing that the client is free to make their own decisions; and focusing on the 
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client’s strengths rather than their weaknesses. Rather than instilling change the MI 
approach suggests that all people possess the necessary resources to bring about 
change and they just need support in unlocking this potential (Miller & Rollnick, 
2012). The MI therapist also employs several techniques with the aim to elicit change 
talk (Miller & Rollnick, 2012). Techniques include exploring the pros and cons of 
behaviour change, reflecting change talk, and imagining extremes such as discussing 
the worst and best thing about making a change. Change talk is also elicited by 
discussing past behaviour and looking to the future, using confidence rulers (rating 
the importance of change and confidence in ability to change) and exploring the 
client’s values and highlighting the discrepancy between current behaviours and 
identified values.  
The therapist moves between and within the process of MI by employing several core 
skills; open questioning, affirming, reflective listening, summarising and informing 
(Miller & Rollnick, 2012). Open questioning encourages reflection and enables the 
therapist to gain access to the client’s internal world and thus allows for more accurate 
empathising. Affirming involves highlighting the client’s existing resources and 
previous successes with regards to behaviour change. Reflective listening comprises 
statements of understanding which help to foster the therapeutic relationship, reduce 
defensiveness and facilitate deeper exploration. Summarising allows the consolidation 
of change talk and can lead to an increase in understanding. Finally, with the client’s 
permission, the therapist provides information and advice relating to the targeted 
behaviour.  
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MI is rarely employed as a “pure” approach and almost all published studies have 
modified the basic MI approach in some way (Burke et al., 2003). MI can be 
delivered as a prelude to treatment, a standalone treatment or in combination with 
other interventions. The most common adaptation of MI is motivational enhancement 
therapy (MET; Miller, Zweben, DiClemente, & Rychtarik, 1992) which combines a 
MI counselling style with personalised normative-based feedback on the target 
behaviour and is usually delivered over four sessions. MET is typically used within 
the context of substance misuse where the person receives feedback on how their 
current drug or alcohol use compares to that of the general population. MI is often 
combined with other treatments such as cognitive-behavioural therapy, education, 
stress management, skills training or pharmacological interventions which can result 
in an additive effect (Anton et al., 2006; Hettema, Steele, & Miller, 2005). As MI is 
typified as a way of being with the client it is suitable for integration with other 
interventions and delivering MI as an adjunct to other effective behaviour change 
therapies is more desirable an approach than pitting them against one another (Miller 
& Rollnick, 2012). 
Effectiveness of MI 
Several systematic reviews and meta-analyses have been conducted to investigate the 
effectiveness of MI. They have demonstrated that MI is associated with small to 
medium effect sizes across a variety of target behaviours including alcohol and drug 
use, diet and exercise, eating disorders and smoking (Burke et al., 2003; Heckman et 
al., 2010; Hettema et al., 2005; Lindson-Hawley, Thompson, & Begh, 2015; Lundahl, 
Kunz, Brownell, Tollefson, & Burke, 2010). MI has also been applied in physical 
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healthcare settings. A medium effect size was found for the association between MI 
and reduction in body mass in overweight and obese patients when compared to 
control interventions (Armstrong et al., 2011). A modest effect was found for MI and 
health outcomes such as dental outcomes, death rate, body weight, alcohol and 
tobacco use, and HIV viral load in a meta-analysis which included 49 trials of MI in 
healthcare settings (Lundahl et al., 2013). A review of MI and medication adherence 
found that MI improves medication adherence in adults when compared to controls 
who had received treatment as usual or an educational intervention (Palacio et al., 
2016). The majority of studies included in the review focused on ART adherence. 
Reviews have demonstrated that studies where there was no specific treatment manual 
yielded double the effect size in comparison with studies where a strict protocol was 
followed (Hettema et al., 2005). It is suspected that a proscriptive MI manual results 
in less flexibility on the part of the therapist to be responsive. For example research 
has shown that implementing a change plan (as instructed by the manual) before the 
client is ready to make a plan for changing behaviour results in poorer outcomes and 
an increase in sustain talk (Amrhein, Miller, Yahne, Palmer, & Fulcher, 2003). Burke 
et al. (2003) found that better outcomes for substance abuse were associated with 
higher doses of treatment (more minutes of MI) and using MI as a precursor to further 
treatment. It has also been found that MI is particularly effective for those with low 
levels of motivation to change the target behaviour (Hettema & Hendricks, 2010). MI 
is best delivered on a one-to-one basis rather than in a group format (Lundahl & 
Burke, 2009). MI takes on average 100 minutes less treatment time than comparable 
interventions such as cognitive-behavioural therapy or 12-step addiction programmes 
such as Alcoholics Anonymous, but can produce equal effects (Lundahl et al., 2010).  
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In a systematic review of ten RCTs of MI interventions targeting HIV risk behaviours 
such as unprotected sex and substance misuse in a population of men who have sex 
with men, Berg et al. (2011) found that MI produced outcomes that were equivalent to 
other treatments or standard care. Another systematic review of MI and HIV risk 
behaviours found that MI had the potential to reduce risky sexual behaviours but the 
effect on substance misuse was inconclusive (Naar-King, Parsons, & Johnson, 2012). 
A systematic review of young people with HIV found evidence to support the effect 
of MI on viral load and condom use but mixed evidence for substance misuse 
(Mbuagbaw, Ye, & Thabane, 2012). A systematic review of MI and ART adherence 
found that three of the five clinical trials studied reported a significant increase in 
adherence rates suggesting that MI holds potential as an intervention to improve ART 
adherence but that further research is needed before definitive claims can be made 
(Hill & Kavookjian, 2012). A recent integrative review of the effectiveness of MI on 
health behaviours in people living with HIV aimed to build on the reviews outlined 
above by focusing on studies published in the previous six years, and by including 
people of all ages and broader measures of health outcomes than just CD4 count or 
viral load (Dillard et al., 2017). MI was shown to have stronger effects when 
integrated with other treatments such as DOT, cognitive-behavioural therapy or 
follow up telephone calls. They found promising evidence for MI (16 out of 19 
studies demonstrating positive effect for MI), either as a standalone or adjunctive 
treatment with regards to reducing symptoms of depression, enhancing adherence to 
ART and reducing risky sexual behaviour in people living with HIV (Dillard et al., 
2017). As can be surmised from these reviews the evidence for the effectiveness of 
MI within the field of HIV is equivocal and further research is needed. However, 
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these reviews also demonstrate that there is evidence to suggest that MI is a promising 
intervention for increasing adherence to ART.  
There are several factors which contribute to MI being an appropriate intervention for 
use in ART adherence. Firstly, MI explicitly focuses on developing a client’s self-
efficacy using confidence rulers, identifying and affirming strengths, and by 
positively reframing past failures at behaviour change (Miller & Rollnick, 2012). 
Self-efficacy is recommended as one of the key predictors to target in adherence 
enhancing interventions (Langebeek et al., 2014). MI has been shown to have larger 
effects in ethnic minority populations in comparison to non-minority white 
populations (Hettema et al., 2005). HIV disproportionately affects certain ethnic 
minorities such as African-American and Hispanic populations in North America 
(Centers for Disease Control and Prevention, 2015) and Black-African populations in 
the UK (Kirwan et al., 2016) hence MI may be an especially effective intervention for 
these minority groups. ART adherence is a complex behaviour and may require a 
multipronged approach to treatment and MI is suitable for integration with other 
interventions such as CBT and reminder devices. Finally, MI is recommended as an 
intervention for enhancing motivation, a key hypothesised determinant of ART 
adherence in the IMB model (Chang, Choi, Kim, & Song, 2014). 
One of the main criticisms that has been levelled at MI is that it lacks a theoretical 
basis (Draycott & Dabbs, 1998). MI was developed organically and intuitively 
through working with people with substance misuse problems and did not arise from 
any particular theory or empirical research (Miller, 1996). Attempts have since been 
made to address this limitation by linking MI to existing psychological theories such 
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as self-determination theory (SDT; Markland, Ryan, Tobin, & Rollnick, 2005; 
Resnicow & McMaster, 2012) and through process research investigating the 
mechanisms of MI.   
Self-determination theory 
SDT is a theory of personality and motivation (Deci & Ryan, 1985). SDT argues that 
humans have an inbuilt need for personal growth and are driven by the desire to 
achieve a unified sense of self and to integrate the self into wider social groups (Deci 
& Ryan, 2002). The theory proposes that to achieve personal growth and well-being 
our innate psychological needs for competence, relatedness and autonomy must be 
met (Deci & Ryan, 2000). Competence refers to a need to feel that it is possible to 
effectively influence the outcome of a situation and experience the opportunity to 
demonstrate this capacity. Relatedness refers to having a sense of belonging or 
connectedness to people and a need to feel cared for and to provide care to others. 
Autonomy refers to feeling that one’s behaviour is volitional and self-endorsed. The 
fulfilment of these psychological needs is necessary for self-motivation (Ryan & 
Deci, 2000).  
Deci and Ryan (2008) propose that motivation lies on a continuum from fully self-
determined to non-self-determined action and the more self-determined a behaviour is 
the more likely a person is to initiate and persist with it. They distinguish between 
different types of motivation: autonomous and controlled, as well as describing the 
absence of motivation or intention to act which they refer to as ‘amotivation’. 
Autonomous motivation lies at the self-determined end of the spectrum where the 
person has chosen and endorsed the behaviour. It is comprised of intrinsic motivation 
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and two forms of extrinsic motivation; integrated and identified. Intrinsic motivation 
involves engaging in a behaviour because it is inherently enjoyable or interesting. 
This type of motivation does not apply to most health-related behaviours including 
medication adherence which is neither interesting nor enjoyable (Patrick & Williams, 
2012). Integrated motivation is where the person identifies with the importance of a 
behaviour and this behaviour is in line with their core values and beliefs. Identified 
motivation is where the person accepts the behaviour as being essential to the 
achievement of personally valued outcomes. Controlled motivation is where 
behaviour is coerced in some way and consists of introjected and external motivation. 
Introjected motivation is where a person is motivated by some internalised self-
esteem related judgement.  The person is viewed as self-controlling by putting 
pressure on themselves to comply with the behaviour to avoid feeling unwanted 
emotions such as anxiety, guilt or shame or to increase feelings of self-worth and 
pride.  External motivation is the most controlled form of motivation and is where the 
person engages in the behaviour to gain a reward or avoid punishment. Amotivation 
represents a lack of intention to act and the person fails to recognise the link between 
action and its outcome.  
Empirical studies have tested SDT across different domains including health, 
education, work and sport. It has been shown that autonomous motivation is linked to 
attendance, engagement with and completion of an alcohol treatment programme 
(Ryan, Plant, & O’Malley, 1995). An RCT found a positive relationship between 
increased autonomous motivation and abstinence from tobacco (Williams, Niemiec, 
Patrick, Ryan, & Deci, 2009). A systematic review has demonstrated that autonomous 
motivation predicts exercise participation (Teixeira, Palmeira, & Vansteenkiste, 
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2012). Hagger et al. (2014) tested the relative contribution of autonomous and 
controlled motivation across different health related behaviours such as having a low 
sodium diet, exercising regularly, drinking alcohol in accordance with healthy 
guidelines and wearing a seat belt. They found that regardless of individual 
differences, autonomous motivation had a larger effect on behaviour across multiple 
health related behaviours than controlled motivation. With regards to medication 
adherence it has been shown that autonomous motivation is linked to successful 
adherence to long-term medication (Williams, Rodin, Ryan, Grolnick, & Deci, 1998) 
and diabetes medication (Williams, Patrick, et al., 2009). Autonomous motivation has 
also been shown to be associated with adherence to ART (Kennedy, Goggin, & 
Nollen, 2004; Lynam et al., 2009).  
In the studies outlined above autonomous and controlled motivation was measured 
through self-report questionnaires such as the Treatment Self-Regulation 
Questionnaire (TSRQ; Williams, McGregor, Zeldman, Freedman, & Deci, 2004), the 
Self-Determination Scale (Sheldon & Deci, 1996), the Behavioural Regulation In 
Exercise Questionnaire (Mullan, Markland, & Ingledew, 1997), and the Integrated 
Regulation Scale (McLachlan, Spray, & Hagger, 2011). While self-report measures 
have the benefit of being economical – saving time and money as they are typically 
easily administered and scored – they do possess limitations and can be unreliable 
(Schwarz & Oyserman, 2001). Self-report measures are vulnerable to the social 
desirability response bias or the tendency for respondents to present a favourable 
image of themselves which can lead to measurement error (Crowne & Marlowe, 
1960). Self-report measures of motivation are limited by the fact that they measure 
motivation to engage in a particular health-related behaviour and ignore the effect of 
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competing goals and the motivation for avoidance of the behaviour (Houston, 
McKirnan, Cervone, Johnson, & Sandfort, 2012). Self-report measures are also 
vulnerable to biases in memory (Schwarz, 2007) and demand characteristics where 
the participant anticipates what the researcher might be expecting to find in the study 
and may bias answers in response (Orne, 1962). Questionnaires are also influenced by 
context and participants’ mood or mental state (Schwarz & Oyserman, 2001). Self-
report measures typically impose a vocabulary or narrative on the participant and thus 
do not allow for exploration of the idiosyncratic motivations a person might have for 
engaging in a behaviour (Houston et al., 2012). Finally, the above SDT questionnaires 
were developed using an expert led top-down process whereby questionnaire items 
were developed from definitions in the literature or by modifying items from existing 
measures. This deductive approach may have limited the content validity of these 
measures and it is argued that participants’ experience should be considered when 
measuring psychological constructs (Brod, Tesler, & Christensen, 2009). Considering 
the extensive limitations of self-report measures and the deductive approach used in 
developing existing measures there is a need to explore alternative inductive ways to 
measure autonomous and controlled motivation.  
SDT has been proposed as a theoretical lens through which the mechanism of MI can 
be better understood for several reasons. Firstly, it is proposed that MI provides 
support for each of the psychological needs for growth proposed by SDT; 
competence, relatedness and autonomy. Competence is supported by MI through 
helping the client to build self-efficacy and confidence by identifying and affirming 
strengths, using confidence rulers, and by positively reframing past failures. The need 
for relatedness is supported within the MI therapy session through the therapist 
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communicating empathy and genuine interest in the client. Finally, MI supports the 
need for autonomy through the therapist adopting a non-expert position, ‘rolling with 
resistance’, eliciting change talk and emphasising that it is entirely the client’s 
decision to change or not (Vansteenkiste & Sheldon, 2006). Both SDT and MI are 
influenced by humanistic psychology with Rogerian concepts such as unconditional 
positive regard and patient-centeredness at the heart of both approaches (Patrick & 
Williams, 2012). A final link between the approaches is both assume that humans 
possess a fundamental inclination for personal growth and that this growth emerges 
from within the person rather than being coerced (Markland et al., 2005).  
Process research 
The variability in outcomes across MI research studies has prompted investigations 
into the mediating and moderating processes of this intervention. It is argued that 
understanding more about the active ingredients of MI will allow for appropriate 
adaptations of this intervention across different populations and will improve clinical 
outcomes, MI training, practice and research (Moyers et al., 2007). Due to the 
relational nature of the MI model both therapist and client responses are viewed as 
key to understanding the processes through which therapeutic change or the 
mechanisms of change occurs within MI sessions (Romano & Peters, 2016). Several 
different process rating systems have been developed to code both therapist and client 
responses during MI sessions (Dobber et al., 2015). The first one to be developed was 
the Motivational Interviewing Skill Code or the MISC (Miller & Mount, 2001). This 
tool has seen various revisions with the most recent version being the MISC 2.5 
(Houck, Moyers, Miller, Glynn, & Hallgren, 2010). It is a numerical coding 
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instrument specifically developed to capture therapist interpersonal style and produce 
frequency counts of specific client and therapist behaviours during MI sessions. The 
MISC 2.5 is superior to other coding systems as it provides detailed categorisations of 
both therapist and client language and incorporates features of two existing coding 
frameworks the MISC 2.1 (Miller, Moyers, Ernst, & Paul C. Amrhein, 2008) and the 
Motivational Interviewing Sequential Code for Observing Process Exchanges 
(SCOPE; Martin, Moyers, Houck, Christopher, & Miller, 2005).  
The language used by both client and therapist has received much attention and 
psycholinguistic analyses of MI sessions form the basis of the MI process research 
studies. It has been shown that the emergence of commitment language (“I am going 
to stop drinking tomorrow.”) is predicted by preparatory change talk namely the 
expression of the desire, ability, reasons and need for change and subsequent 
behaviour change is predicted by the strength of that commitment language 
particularly towards the end of the session (Amrhein et al., 2003). It has also been 
found that MI-consistent responses (“You’re a very resourceful person”) tend to be 
followed by change talk whereas MI-inconsistent responses (“You’re going to relapse 
if you don’t get out of this relationship”) were more likely to be followed by sustain 
talk (Moyers et al., 2007). It also followed that change talk elicited further MI-
consistent utterances from the therapist thus setting up a symbiotic relationship.  
A number of studies have focused on analysing therapist interpersonal style during the 
session and the impact on outcomes. It has been found that therapists who are more 
client-centered and less confrontational experience less client resistance during 
sessions which was associated with long-term reductions in alcohol use (Miller, 
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Benefield, & Tonigan, 1993). High levels of therapist empathy has been demonstrated 
to be associated with a reduction in alcohol use in a group of hazardous drinkers 
(Gaume, Gmel, & Daeppen, 2008). Baird et al. (2007) found that therapists who 
focused on fostering an emotionally supportive relationship with the client were less 
likely to have clients drop out of treatment and consequently experienced better 
outcomes. It has also been shown that therapist displays of MICO methods directly 
facilitate client engagement in the therapeutic process as demonstrated through 
expression of affect, disclosures made and cooperation during the session (Moyers, 
Miller, & Hendrickson, 2005).  
Causal model of MI 
A hypothesized causal model of MI (see Figure 1) was developed by Miller and Rose 
(2009) and informed by MI process research. This model proposes relational and 
technical pathways through which behaviour change occurs within the context of MI 
sessions (Miller & Rose, 2009).  The relational component focuses on the therapist 
conveying MI spirit and empathy. MI spirit encapsulates adopting a compassionate 
and collaborative communication style while encouraging autonomy and evoking 
motivation to change (Miller & Rollnick, 2012).  The technical component 
hypothesises that the therapist use of MICO methods (such as empathising, reflective 
listening and evoking reasons for change) will elicit and reinforce client change talk, 
which has been shown to predict behaviour change (Apodaca & Longabaugh, 2009) 
while overlooking instances of sustain talk where the client favours maintaining the 
status quo. The model also suggests that training in MI is directly related to therapist 
empathy and MI spirit, therapist use of MICO methods, client expression of change 
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talk and diminished resistance during MI sessions. The model proposes that both the 
relational and technical components of MI can either have a direct or mediated (by 
client change talk) impact on targeted behaviour change.  
 
Figure 1 Causal model of MI adapted from Miller and Rose (2009) 
 
Several reviews of the MI model (Miller & Rose, 2009) have been undertaken and 
evidence has been found in support of parts of the model (Apodaca & Longabaugh, 
2009; Copeland, McNamara, Kelson, & Simpson, 2015; Magill et al., 2014; Romano 
& Peters, 2016). Apodaca and Longabaugh (2009) were the first to review the process 
research evidence, focusing on substance misuse. Due to a paucity of full causal 
studies they were only able to identify potential mediators. They found strong 
evidence for the hypothesised relationship between increase in change talk and 
behaviour change. Magill et al. (2014) carried out an aggregate test of the technical 
pathway using meta-analytic methods within the context of addiction (substance 
misuse and gambling). The a path (therapist MI skills in relation to client change talk) 
and b path (client change talk in relation to behaviour outcomes) of the mediational 
chain was tested. Evidence for the relationship between therapist use of MICO 
methods and client change talk was found but contrary to the model there was no 
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significant relationship observed between MICO methods and client sustain talk. As 
expected therapist use of MI-inconsistent methods was associated with less client 
change talk and an increase in client sustain talk. In contrast to Apodaca and 
Longabaugh (2009) there was no evidence found to support the hypothesised 
relationship between increased client change talk and behaviour outcome. However 
true to the model there was an association found between increased client sustain talk 
and worse outcomes. All effect sizes reported in the meta-analysis were small.   
A review of the MI model within the context of health behaviours (Copeland et al., 
2015) found that MI spirit was associated with increased client change talk which in 
turn was found to be related to improvement in health outcomes such as healthy diet, 
exercise, weight loss and medication adherence. Due to the small number of process 
research studies existing within the context of health behaviours it was not possible to 
draw conclusions about any other aspects of the MI model. Romano and Peters (2016) 
systematically reviewed the existing evidence for each pathway in the MI model 
across a range of target behaviours (substance misuse, exercise, diet, medication 
adherence, intimate partner aggression, and smoking). They found that evidence was 
strongest for the technical component namely that therapist use of MI-consistent 
methods was positively associated with client change talk; with therapist use of 
reflections being particularly instrumental. It was found that client change talk was 
unlikely to occur following MI-inconsistent therapist behaviours. With regards to the 
relational pathway the results were inconsistent across studies which the authors 
conclude may link to challenges in accurately measuring MI spirit and empathy. 
Replicating other review studies (Apodaca & Longabaugh, 2009; Copeland et al., 
2015), client change talk was found to be associated with behaviour change outcomes.  
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Considering the results from these reviews together, there is consistent evidence to 
confirm the technical pathway of the MI model namely that therapist use of MI-
consistent methods is associated with increased client change talk and therapist use of 
MI-inconsistent methods is associated with reduced client change talk. The evidence 
regarding the relational component of the model is inconclusive, although it is 
possible that MI spirit might be a promising active ingredient particularly in the 
context of health behaviours. The majority of these reviews support the proposed 
relationship between increased client change talk and behaviour change. Given the 
inconsistent findings further process research is needed, particularly within the 
context of health behaviours, to gain a better understanding of the causal model of MI. 
Methodological issues of process research 
There are important methodological issues that must be considered when reviewing 
the process literature. MI process research typically relies on human raters who often 
do not agree with one another. Disagreement between coders results in measurement 
error within the ratings (Holsclaw, Hallgren, Steyvers, Smyth, & Atkins, 2015).  
According to Kazdin and Nock (2003) to demonstrate that a variable does indeed act 
as a mechanisms of change certain criteria must be fulfilled. A strong association is 
necessary to show that there is a causal mechanism existing between variables. The 
second criterion is specificity or demonstrating that the proposed mechanism accounts 
for the change while showing other conceivable variables do not act as mediators. 
Another important criterion is showing that increasing the identified change 
mechanism will result in a greater change in the linked outcome. The use of an 
experiment through which the mechanisms can be manipulated and potential 
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confounding variables can be controlled, is necessary to infer causality. It is also 
important to show that the relationship is temporal whereby the alteration in the 
change mechanism preceded the change in the targeted outcome variable. 
Demonstrating consistency and replicability of the change processes across different 
contexts and samples is essential. The final criterion is that the proposed mechanism 
is plausible within the context of the existing knowledge base. The more criteria 
satisfied the stronger the argument for causality (Kazdin & Nock, 2003). It is a near 
impossible task to achieve all of these criteria with just one study and instead it is 
recommended that findings are aggregated across studies so that all criteria are met 
(Nock, 2007).  
MI process research & HIV 
Investigation of the mechanisms of MI outside the context of substance misuse 
remains limited (Romano & Peters, 2016). Given the variety of effect sizes reported 
across studies and behaviour outcomes it is possible that the mechanisms of change 
differ across targeted behaviours. As MI has been shown to be a promising 
intervention to enhance ART adherence and reduce risky sexual behaviour in people 
living with HIV (Dillard et al., 2017) it is important that we conduct process research 
to gain a better understanding of the actions of change within a HIV context. There 
have been only two process research studies published with this population.  
Grodensky et al. (2017) examined if the quality of MI was related to risky sexual 
behaviour in adults attending a HIV clinic in North America. The MISC 2.0 (Miller, 
Moyers, Ernst, & Amrhein, 2003) was applied to an MI session of 32 participants 
who were randomly selected from a larger RCT. The behaviour outcome was the 
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number of times a participant had unprotected vaginal or anal intercourse in the 
previous three months and this was collected using a self-report survey at the 8-month 
follow-up. The relational pathway was partially upheld as therapist acceptance, MI 
spirit and empathy were all positively correlated with fewer incidents of unprotected 
vaginal/anal intercourse. With regards to the technical component of the model only 
the ratio of therapist reflections to questions was found to be associated with 
behaviour outcome. The study was limited by the small sample size and the fact that 
baseline rates of unprotected anal/vaginal intercourse do not appear to have been 
factored in to the analysis. Also, this study did not take client change language into 
account, which has been shown to be a key aspect of the causal MI model (Miller & 
Rose, 2009).  
One published study has explored MI processes within the context of ART adherence 
(Thrasher et al., 2006). One of the aims of this study was to investigate the 
relationship between ART adherence outcomes and measures of MI session quality 
and therapist behaviours. Baseline adherence as measured by pill counts was an 
average of 56% of doses taken across the study. There were 35 participants for whom 
adherence data was available for both weeks 4 (pre-MI session) and 12 (post-MI 
session/study exit). Spearman’s correlational coefficients showed a significant 
positive association for week 12 ART adherence and both number of affirming 
statements made and a higher ratio of reflections to questions asked (indicators of MI-
consistent therapist methods). There was a negative association found between ART 
adherence and closed questions (indicator of MI-inconsistent therapist methods). 
However there were a number of limitations to this study. Client behaviours, a key 
aspect of the MI model (Miller & Rose, 2009) was not taken into account as part of 
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this study. The influence of pre-MI session adherence data (week 4) was not 
accounted for in the statistical analysis. There was an increase in the possibility of 
type 1 errors due to the fact that a variety of different therapist MI measures were 
tested for associations. Finally, the sample of participants with full outcome data was 
relatively small (n= 35) thus limiting the generalisability and power of the study. 
Thrasher et al. (2006) call for future research to build on their research by 
investigating the potential mediating role of client change talk in a larger research 
sample.  
Research aims & hypotheses  
This study aims to build on the study carried out by Thrasher et al. (2006) by testing 
both the relational and technical pathways of the MI model in relation to ART 
adherence taking both client and therapist factors of the model into account. This 
study will improve on the Thrasher et al. (2006) study by taking pre-MI session 
adherence data into account and by testing the MI model in a larger sample. This 
study will look at schedule adherence as it is important to maintain a continuous 
coverage of ART within the blood to minimise the risk of drug resistance. This study 
also aims to use an outcome variable that is measured close to the MI session (one 
week later) as advised by Longabaugh (2007). 
A secondary aim of the study is to explore the relationship between ART adherence 
and more fine-grained naturally occurring motivational speech than MI specifies; 
namely autonomous and controlled motivation (Deci & Ryan, 2008). Autonomous 
motivation has been shown to have a stronger relationship with health related 
behaviours than controlled motivation does (Hagger et al., 2014) therefore it is 
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predicted that ART adherence will be more closely associated with autonomous than 
controlled motivation. Autonomous motivation is usually measured using self-report 
measures however as noted previously these questionnaires can be unreliable 
measurement tools and do not always consider the perspective of the participant. This 
study aimed to measure autonomous and controlled motivation using an inductive 
approach through the observational method of coding naturally occurring speech. 
Existing observational coding tools such as the MISC only identify broad categories 
of change language and do not capture information relating to the motivations for 
behaviour change hence it will be necessary to develop a novel coding tool to capture 
autonomous and controlled motivation to adhere to ART.  
The research hypotheses are:  
1. Client change talk during MI session 1 will mediate the relationship 
between therapist use of MICO methods in MI session 1 and post-session 
change in ART adherence (see Figure 2).  
 
Figure 2 Research hypothesis 1 
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2. Client change talk during MI session 1 will mediate the relationship 
between therapist MI spirit in MI session 1 and post-session change in ART 
adherence (see Figure 3). 
 
Figure 3 Research hypothesis 2 
 
3. Higher levels of ART adherence will be more closely associated with 
naturally occurring autonomous motivation talk than controlled motivation 
talk expressed during MI session 1. 
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Chapter 2: Method 
Research design 
This study is a secondary analysis of the relationship between ART adherence and 
client and therapist speech within motivational interviewing therapy sessions. It 
employs both a cross-sectional and longitudinal design.  The therapy sessions were 
collected as part of Project MOTIV8, an RCT exploring the use of MI alone and in 
combination with another treatment (outlined below) to increase ART adherence in 
adults living with HIV (Goggin et al., 2013). Therapy sessions were analysed (cross-
sectional component) using two separate coding systems; the Motivational 
Interviewing Skills Code (MISC) 2.5 (Houck et al., 2010) and a novel coding system 
the SDT & Medication Adherence Coding System (SMACS) which was developed 
specifically for this study. ART adherence data was gathered at various points 
throughout the study (longitudinal component) using an electronic medication 
monitoring device.        
Overview of project MOTIV8 
Participants enrolled in the 48-week research trial (n=204) were randomised to one of 
three arms: 1) a standard care (SC) group receiving usual medical care (n=65, 32%); 
2) an enhanced counselling (EC) group receiving 10 sessions of MI-based adherence 
counselling (n=70, 34%) and 3) an enhanced counselling/observed therapy (EC/OT) 
group receiving 10 sessions of MI-based adherence counselling alongside the 
supervision of a portion of daily medication doses (n=69, 34%) for 24 weeks.   
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Participants of MOTIV8 
Participants for the MOTIV8 study were recruited from six outpatient clinics in a 
mid-West city in the United States of America. Eligible participants were HIV 
positive, over the age of 18, English-speaking, and taking ART for the first time, 
changing their ART regimen or having self-reported or doctor suspected ART 
adherence difficulties as evidenced by clinical viral load (HIV RNA >1,000 
copies/ml). Participants were excluded if they lacked the cognitive capacity to 
consent, were pregnant, did not self-administer their medication, had an acute illness, 
planned a move that might interfere with participation in the study, or lived outside 
the specified catchment area.   
Procedure of MOTIV8 
Informed consent was obtained for eligible participants who expressed interest in 
taking part in the MOTIV8 study. Baseline assessment of demographic, adherence, 
psychosocial and physical health indicators was conducted by different project staff 
from those providing interventions using an Audio Computer Assisted Self Interview 
which presents information both on-screen and as an audio recording.   
After completing baseline assessments, participants were randomised into one of the 
three groups. Those randomised for MI-based adherence counselling (EC and EC/OT 
groups) were scheduled for six one-to-one sessions (baseline, weeks 1, 2, 6, 11, and 
23) and four telephone sessions (weeks 4, 9, 15, and 19). Therapy sessions lasted, on 
average, 25 minutes. The baseline session consisted of information provision 
regarding the importance of correct adherence and subsequent therapy sessions used 
one of a selection of 11 skill-building modules (e.g., motivation enhancement, self-
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monitoring, goal setting, and problem solving). MI for motivation enhancement was 
always the focus of the week 1 therapy session and consecutive sessions either 
repeated the MI module or focused on one of the other skill-building modules 
(Goggin et al., 2013).  
Counsellors 
Master’s degree level professionals received training in MI, behavioural skills 
building through cognitive-behavioural techniques, HIV and medication adherence. 
MI training was delivered by a licensed clinical psychologist with expertise in MI 
through a day-long workshop and supervised role-plays. Before delivering therapy 
sessions all counsellors were required to demonstrate proficiency in MI skills 
alongside other study protocol elements. All sessions were audio recorded and 
counsellors received regular supervision throughout the study in which random tapes 
were selected and assessed for fidelity to MI principles using a 26-item coding 
scheme adapted from an earlier study (Harris et al., 2010). 
Measures of MOTIV8 
All participants completed a number of measures at various time-points throughout 
the study including at baseline (before randomisation occurred). This secondary 
analysis includes the following measures: 
Demographic & health information. 
Baseline demographic information included; age, gender at birth, education level, 
employment status, sexual orientation and ethnicity. Clinical characteristics specific 
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to HIV were gathered at baseline and included; CD4 cell count, viral load copies, and 
if the participant was starting ART for the first time or not.   
Depressive symptoms. 
Participants’ depressive symptoms (behavioural, emotional, cognitive and somatic) 
over the previous week were collected at baseline using the 20-item self-report Centre 
for Epidemiologic Studies Depression Scale (CES-D; Radloff, 1977). Each item is 
rated on a 4-point scale ranging from 0 = rarely or none of the time (less than 1 day) 
to 3 = most or all of the time (5 – 7 days). Higher scores indicate greater levels of 
depressive symptoms with scores above 16 indicating the likelihood of clinical 
depression being present. Radloff (1977) demonstrated that the CES-D has sufficient 
reliability (Cronbach’s alpha = .85 – .90, split-half and Spearman-Brown = .77 – .92) 
and validity (concurrent with other depression scales and discriminates between 
psychiatric inpatient and general population). Item response theory has been used to 
demonstrate that the CES-D is suitable for use as a measure of depression (Olino et 
al., 2012). The CES-D has also been shown to be appropriate for use in a population 
of people living with HIV (Cockram, Judd, Mijch, & Norman, 1999).  
ART adherence. 
ART adherence data was collected using an electronic pill-cap known as a Medication 
Events Monitoring System or MEMS cap. This device captures the date and time 
when a medication bottle is opened allowing for more accurate data regarding ART 
adherence in comparison to other methods such as self-report and pharmacy refills 
(Farley et al., 2003; Müller et al., 2008). Participants were required to keep one of 
their ART medications in the MEMS cap bottle. Those taking more than one ART 
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medication choose the medication with the most complex dosing schedule for the 
MEMS cap bottle or the drug anticipated to cause the most severe side effects when 
the dosing schedule was identical across all ART medications. Adherence data was 
downloaded and cleaned to safeguard against any participants registering an 
adherence value of greater than 100% in any 24-hour period. Data was excluded if a 
participant was unable to use the MEMS cap due to being in hospital, in prison or on a 
period of strategic treatment interruption as advised by their healthcare provider. Two 
measures of ART adherence data were calculated as follows: 1) the percentage of 
prescribed ART doses taken (number of doses taken divided by the number of doses 
prescribed) and 2) the percentage of prescribed ART doses taken on time (within 2 
hours either side of the scheduled dose time). For the purpose of this study, ART 
adherence percentages were calculated at three separate intervals: 1) week 1 (the 7 
day period before the first MI session); 2) week 2 (the 7 day period after the first MI 
session); and week 12 (30 days of adherence data prior to 12th week of the trial).        
Motivation to adhere.  
A brief self-report measure capturing baseline motivation to adhere to ART was 
devised for the MOTIV8 study. This measure required participants to rate on scales 
from 0 = not at all to 10 = extremely their need, reasons, readiness, wish and 
commitment to adhere strictly to the ART schedule. This measure was informed by 
the work of Amrhein et al. (2003) on language reflecting commitment or motivation 
to change. Following an investigation of the factor structure and reliability of the 
measure, one item (wish/want to adhere) was dropped and the remaining four items 
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achieved good internal consistency (α = .83). Therefore, the mean response to the 
four-item version of the measure was used for the current study. 
Autonomous and controlled motivation. 
Baseline autonomous and controlled motivation was assessed using the TSRQ 
(Williams et al., 2004) which is a self-report measure of motivation to engage in a 
health-related behaviour, for example medication adherence. Responses are captured 
on a 7-point Likert-type scale, ranging from 1 = not at all true to 7 = very true. The 
items are divided into two subscales measuring autonomous and controlled motivation 
(6 items each). Both subscales have demonstrated sufficient internal consistency 
within the context of diabetes medication adherence. The autonomous subscale 
demonstrated good internal consistency (α = .86) while the internal consistency of the 
controlled subscale was adequate (α = .75). A validation study in a group of adults in 
North America across smoking, diet and exercise has shown the TSRQ to be a valid 
and reliable tool (Levesque et al., 2007) demonstrating sufficient internal consistency 
across all subscales and populations (α > .73), confirmatory factor analysis supported 
subscales and significant correlations were achieved with related health measures. 
The autonomous subscale of the TSRQ has been used in a study of ART adherence in 
adults living with HIV (Kennedy et al., 2004) and achieved good internal consistency 
(α = .81). As per usual practice the TSRQ items were modified to reflect the health 
behaviour of interest, namely ART adherence.  
Sample  
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Power calculation 
The number of participants required for the current study was calculated using an a 
priori power analysis. The study was powered to test for the indirect effect of therapist 
use of MICO methods on ART adherence via client change talk (hypothesis 1) using 
bootstrapping approaches to mediation analysis. As this hypothesis tests components 
of the causal model of MI (Miller & Rose, 2009) in a new population, it was not 
possible to anticipate precisely what the mediated effect sizes might be. However, a 
power analysis was informed by considering the model and results reported for 
substance misuse population in a study using a similar design (Moyers, Martin, 
Houck, Christopher, & Tonigan, 2009). In Moyers et al. (2009) the relationships 
between both therapist use of MICO methods and drinks per week and client change 
talk were medium. Therefore, a medium effect size for both the a path (therapist use 
of MICO methods and client change talk) and b path (client change talk and ART 
adherence change) was anticipated for the current study. A power calculation was 
informed by Fritz and MacKinnon (2007), giving an estimated sample size of between 
71 (bias-corrected bootstrap) and 78 (percentile bootstrap) participants to provide 
80% power, at an alpha level of  p = .05 with a medium effect size for both a and b 
pathways. A sample size of 75 participants was chosen as it is the mid-point between 
the two estimated sample sizes. 
Sample selection 
This study focused on coding the first MI counselling session given that this was 
delivered to all participants in the MI arms of the RCT. Focusing on the first MI 
session brings this study in line with other MI process research allowing for 
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comparison across studies and reduces the risk of selection bias that may have been 
introduced through study attrition.  
One hundred and thirty-nine participants were randomised to receive the MI 
intervention. Due to the ceiling effect noted in the data whereby participants reported 
high motivation to adhere to ART, this secondary analysis focuses on those 
participants with lower baseline adherence motivation (mean motivation to adhere < 
10, n = 65). Ten participants with high baseline motivation to adhere (mean 
motivation to adhere = 10) were randomly selected to achieve a sample size of 75 
required to sufficiently power the study.  
Of this identified sample of 75, two audio files were missing and in one session the 
client spoke in both Spanish and English throughout. Therefore, these three 
participants were excluded from the study. Due to time constraints, it was not possible 
to code all remaining 72 sessions leaving a final sample size for analysis of 66 
sessions. Twelve sessions were randomly selected from the remaining sessions not 
selected for inclusion in this study – those who reported higher baseline levels of 
motivation – for coding training and the development and piloting of the SMACS.  
Sample characteristics 
Baseline demographic (age, gender at birth, ethnicity, education level, employment 
status and sexual orientation) and clinical (depression symptoms, first time taking 
ART, baseline viral load and CD4 count) information for the final sample included in 
the current study (n=62) are presented in Table 1.   
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Table 1 Participant demographic information  
 All Participants 
Variable Mean (SD) No (%) 
Age, years 40.06 (10.10)  
Male gender at birth  46 (74.2) 
Ethnicity   
 African-American  33 (53.2) 
 White  23 (37.1) 
 Mixed  5 (8.1) 
 Other  1 (1.6) 
Education   
 High School Degree or Less  31 (50.0) 
 More than High School Degree  31 (50.0) 
Sexual Orientation   
 Heterosexual   27 (43.5) 
 Homosexual  26 (41.9) 
 Bisexual  6 (9.7) 
 Other  1 (1.6) 
 Choose not to answer  2 (3.2) 
Employment   
 Full-time  9 (14.5)  
 Part-time  6 (9.7) 
 Not currently employed  47 (75.8) 
Depressive symptoms   
 Above clinical threshold  36 (58.1) 
First time taking ART  18 (29.0) 
Viral Load (copies/ml) – Baseline  121925.51 (156203.67)  
CD4 count (cells/mm3) – Baseline  264.11 (177.71)  
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Participants ranged in age from 19 to 61 years with a mean age of 40 years. There was 
diversity in the sample with regards to sexual orientation with the majority of the 
sample (51.6%) identifying as either homosexual or bisexual. A large proportion of 
the sample (58.1%) scored above the clinical threshold (>16) for depression as 
measured by the CES-D (Radloff, 1977). The average baseline disease indicators 
(CD4 count and viral load) were poor. Healthy CD4 counts are between 500–1,600 
cells/mm3, whereas the mean level in this samples was just 264.11 cells/mm3. The 
mean viral load was 121,925.51 copies/ml and <50 copies/ml is required to achieve 
undetectable levels of HIV virus in the blood.  
This sample is representative of the population of people living with HIV in North 
America with men who have sex with men and African-Americans being 
disproportionally affected by HIV (Centers for Disease Control and Prevention, 
2015).  
Ethical approval 
Approval for the original RCT (project MOTIV8) was obtained from the Institutional 
Review Boards at each recruitment clinic and at the North American University 
leading the research study. The consent form for the original study (Appendix 1) 
advised participants that the audio tapes from the counselling sessions would be saved 
indefinitely and could be used on future projects investigating the effectiveness of the 
counsellors and the style of counselling. The principal investigators who collected the 
original data gave additional permission for the data to be used for the purpose of this 
study. The current study was granted ethical approval from Royal Holloway, 
University of London Research Ethics Committee (REC) in May 2016 (Appendix 2). 
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The study was informed by relevant research ethics guidelines including the Code of 
Human Research Ethics (BPS, 2014) and the Royal Holloway University of London 
Research Ethics Guidelines (2010). As this study was a secondary data analysis of a 
research study which had been previously granted full ethical approval the main 
ethical issue to consider was confidentiality. Due to the sensitive nature of the data all 
audio files and existing transcripts were transferred using a secure method of file 
transfer. The participants were not identifiable. All transcripts were anonymised 
during the parsing stage and prior to double-coding by research assistants. All data 
were stored securely on the Royal Holloway University of London Psychology 
Department network drive and files were transferred to research assistants using 
encrypted USB flash drives.  
Coding process 
Coding tools 
All transcripts were parsed (separated into speech units) and coded by the researcher 
and any queries were resolved through discussion with the research supervisor who is 
a clinical and research psychologist and an expert in HIV and MI. Two undergraduate 
psychology students were recruited as research assistants to support with establishing 
the inter-rater reliability of both coding tools. The coding systems used in the current 
study are described in detail below.  
Motivational Interviewing Skills Code (MISC) 2.5 
The MISC 2.5 (Houck et al., 2010) incorporates features of two existing coding 
frameworks the MISC 2.1 (Miller et al., 2008) and the Motivational Interviewing 
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Sequential Code for Observing Process Exchanges (MI–SCOPE; Martin et al., 2005) 
and aims to capture more accurately the subtleties of both therapist and client speech. 
Coding is conducted in a series of three separate coding passes. In the first pass, the 
coder listens to the MI session straight through and records global ratings of the 
therapist on six dimensions; acceptance, empathy, direction, autonomy support, 
collaboration and evocation (See Table 2). Global ratings are made on a 5-point Likert 
scale, with the coder instructed to assume a beginning score of “3” and to move up or 
down from there. The value for MI spirit is derived by calculating the mean value 
across the global ratings of autonomy support, collaboration and evocation.  
Table 2 Global codes as defined by the MISC 2.5 
Global Code Definition 
Acceptance The extent to which the therapist communicates unconditional 
positive regard for the client.  
Empathy The extent to which the therapist demonstrates accurate 
understanding of the client’s perspective. 
Direction The degree to which the therapist maintains focus on the targeted 
behaviour for change.  
Autonomy Support The extent to which the therapist supports and fosters the client’s 
perception of choice to change or not.  
Collaboration The degree to which the therapist acts as if the session is 
occurring between two equal partners 
Evocation The degree to which the therapist conveys that motivation resides 
in the client and focuses to elicit this motivation during the 
session. 
  
In the second pass, the therapy session is parsed into separate speech utterances or 
thought units (Gottman, Markman, & Notarius, 1977) so that the individual utterance 
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can be assigned the appropriate code. Once parsing is complete, the coder carries out 
a final pass which involves listening to the session and assigning both therapist and 
client utterances a behavioural code as described in the coding manual. Before this 
process begins the target behaviour must be clearly defined. In the case of the current 
study taking ART as prescribed was the target behaviour. Each speech utterance can 
only be assigned one code. During the coding process, the audio of the session may be 
paused as often as necessary to determine the appropriate code to be assigned to each 
speech utterance.  
The MISC 2.5 offers 25 possible codes for therapist language which can be grouped 
into broader categories. The focus of this study was MICO responses which is 
comprised of the following codes; advise with permission, affirm, emphasise control, 
open question, simple reflections, complex reflections, support, and raise concern 
with permission. See Table 3 for definitions and examples of each code.  
Client language is coded into three broad and mutually exclusive categories; change 
talk, sustain talk and follow/neutral/ask. Change talk and sustain talk are made up of 
specific categories of change language either towards or away from change (desire, 
ability, reason, need, taking steps, other and commitment language) reflecting the 
client’s current or future state of mind. All other client speech is coded as 
follow/neutral/ask. See Table 4 for definitions and examples of each code.  
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Table 3 Codes for MICO responses 
Code Definition Example 
Advise with 
permission 
With permission therapist gives 
advice or offers a solution.   
“Would it be all right if I 
suggested something?” 
Affirm Statements that are positive or 
complementary.  
“You’re a very resourceful 
person” 
Emphasise control Emphasises client’s freedom of 
choice, autonomy and personal 
responsibility.  
“It’s your decision” 
Open question Questions that allow clients to 
expand on their response.  
“How might you be able to do 
that?” 
Simple reflection Statements that rephrase or 
restate what the client has said.  
C: “I want to, but I don’t want 
to” 
T: “You want to change, but you 
don’t want to” 
Complex reflection Statements that restate what 
client said with added meaning 
C: “I want to, but I don’t want 
to” 
T: “You want to change, but the 
comfort of old habits also has a 
strong pull” 
Support Sympathetic, compassionate or 
understanding responses. 
“That must have been difficult” 
Raise concern with 
permission 
With permission therapist points 
to a possible problem or 
negative consequence that they 
are concerned about. 
C: “What do you think about 
that idea? 
T: “Well, frankly it worries me” 
 
.
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Table 4 Codes for client speech 
Code Definition Example 
Change Talk   
Commitment Explicit expressions of intention to change behaviour. “I am going to take my meds on time today” 
Reason Statements about reasons for changing behaviour.  “Life will be better if I take my ART” 
Desire Statement of desire to change behaviour.  “I don’t want to live like this anymore” 
Ability Expresses confidence in ability or capacity to change behaviour. “I know that I can take my ART on time” 
Need Statement of need to change behaviour. “I need to take my meds” 
Taking Steps Refers to recent changes the client has made.  “I took my meds on time two days last week” 
Other Language related to change but does not fit other categories.  “If I were to get pregnant I would take my ART” 
Sustain Talk   
Commitment Explicit expressions of intention to maintain status quo. “I’m not going to take my meds at all” 
Reason Statements about reasons to maintain status quo. “I get terrible side-effects from my meds” 
Desire Statement of desire to maintain status quo. “I don’t like taking my ART” 
Ability Explicit expression of inability to change behaviour. “I cannot swallow the pills” 
Need Statement of need to maintain status quo. “I don’t need to take my meds” 
Taking Steps Refers to recent behaviour in the direction away from change.  “I’ve haven’t bothered picking up my meds” 
Other Statement of maintaining status quo that does not fit other categories.  “It’s not important to change” 
Follow/ 
Neutral/Ask 
Responses not related to the target behaviour, asking questions or 
reporting information or history.   
“I was first prescribed ART a decade ago” 
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For the purpose of this study the MISC 2.5 was used to derive the sum of MI-
consistent responses, change talk and sustain talk for each session as this related to the 
hypotheses of the study.  
SDT & Medication Adherence Coding System (SMACS) 
For the purpose of the current study a novel coding system was developed to quantify 
naturally occurring speech in MI sessions which encapsulates autonomous and 
controlled motivation to adhere to ART medication. The initial stage of developing 
the manual involved a review of the relevant SDT literature to gain a deeper 
understanding of the differences between autonomous and controlled motivation. 
Following this, eight transcripts which had been excluded from the main analysis 
were reviewed to identify all references to the clients’ motivation to adhere to their 
ART. These reasons for wanting to adhere were categorised as being either 
autonomous or controlled motivation and were used as examples for each category in 
the coding manual. Additional examples were generated following a review of the 
literature and existing measures of autonomous and controlled motivation. There were 
eight reiterations of the manual as it went through extensive piloting and consultation. 
The researcher and supervisor piloted the manual by independently coding four 
further excluded transcripts using the SMACS. The ratings were compared and codes 
were agreed to produce gold-standard transcripts for the purposes of training. The 
manual was further refined and extended on the basis of coding meetings following 
this piloting process. Feedback was sought from service user representatives (n=2; 
male and female) from CHIVA (Children’s HIV Association; a national UK charity 
for children and young adults living with HIV) who were over the age of 18, living 
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with HIV and currently taking ART. The manual was further refined and targeted 
examples were added to the manual such as this example of controlled motivation “I 
take my medication because I have no choice”. The final SMACS manual (see 
Appendix 3) requires the coding of all parsed client speech (as parsed using the MISC 
2.5) as either autonomous motivation, controlled motivation or non-motivational 
client speech. The construct validity of this coding scheme will be explored by 
correlating the results with baseline scores on the TSRQ (Williams et al., 2004). 
Coding training 
MISC (2.5) training 
The main researcher spent 30 hours training in the use of the MISC 2.5 while the 
research assistant spent 15 hours in training. Training followed the procedures 
outlined in Moyers and Martin (2006) and included identifying therapist questions 
and reflections, client questions, then moving to classifying the content of therapist 
and client speech, identifying different categories of change and sustain talk and MI-
consistent and inconsistent responses. Dr Jon Houck (MISC 2.5 author) provided five 
sample gold-standard coded transcripts to the researcher which were used for training 
purposes. Parsing training was based on these transcripts. Coding was carried out 
using NVivo qualitative data analysis software version 11 (QSR International, 2015). 
The main researcher achieved a mean Cohen’s (1960) kappa result of .8 (almost 
perfect agreement; Landis & Koch, 1977) across all three higher order categories of 
interest (MICO responses, change talk, sustain talk) while the research assistant 
achieved at least .7 (substantial agreement; Landis & Koch, 1977).      
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SMACS training 
The second research assistant received 10 hours of training in the SMACS. This 
involved reading key SDT literature and one-to-one teaching on using the coding 
manual. The excluded transcripts used during the piloting phase of the SMACS 
development where the codes had been agreed between the researcher and supervisor 
(n = 4), served as gold-standard transcripts for the purposes of training. Coding was 
carried out using Excel 2016. The research assistant achieved a mean Gwet’s (2008) 
AC1 of .9 (almost perfect agreement; Landis & Koch, 1977) across the three 
categories before commencing reliability-testing.  
Reliability-testing 
As the MISC 2.5 has never been applied to a HIV population and the SMACS is a 
novel coding tool it was necessary to establish the inter-rater reliability of both coding 
systems. A proportion of the research sample were randomly selected for double 
coding using a random number generator. Twelve sessions (22%) were double coded 
using the MISC 2.5 and 15 sessions (28%) were double coded using the SMACS. It is 
recommended that at least 20% of the sample should be double-coded when 
establishing inter-rater reliability for MI process research studies (Dobber et al., 
2015). To prevent coding drift, coding meetings were held following every three 
sessions coded using the MISC 2.5 and every five sessions with the SMACS. 
Consultation was provided by the research supervisor for any outstanding 
disagreements following coding discussions. Inter-rater reliability estimates were 
interpreted using standard criteria. Both Kappa and Gwet’s AC1 statistics were 
interpreted according to Landis and Kock (1977) guidelines with values from .0 to .20 
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indicating slight agreement, .21 to .40 indicating fair agreement, .41 to .60 indicating 
moderate agreement, .61 to .80 indicating substantial agreement, and .81 to 1.0 
indicating almost perfect or perfect agreement. ICC results were interpreted according 
to guidelines by Cicchetti (1994) whereby results less than .40 are poor, between .40 
and .59 are fair, between .60 and .74 are good and results above .75 indicate excellent 
levels of inter-rater reliability.     
Cohen’s kappa (1960) was used to test the inter-rater agreement for the client and 
therapist speech on the MISC 2.5 as it is commonly used for assessing agreement 
between categories and is suitable for use with two coders and for fully-crossed 
designs which is where all coders code the data to establish inter-rater reliability 
(Hallgren, 2012). See Table 5 for the inter-rater reliability estimates for therapist and 
client speech as coded using the MISC 2.5 which indicated substantial agreement 
(Landis & Koch, 1977). The percentage agreement is also reported for reference.  
Table 5 Inter-rater reliability of therapist & client speech using MISC 2.5 
Variable Kappa 
Percentage 
Agreement 
Change Talk .69 92.21 
Sustain Talk .65 96.67 
Follow/Neural/Ask .71 90.70 
MICO Responses .77 91.55 
   
As the global coding section of the MISC 2.5 produces continuous data the inter-rater 
reliability for MI spirit was calculated using intra-class correlations (ICC; McGraw & 
Wong, 1996). There are a number of ICC variants to choose from (Hallgren, 2012). 
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As it was a fully-crossed design, a two-way mixed ICC was most appropriate. The 
coding required perfect agreement between the two raters therefore an absolute 
agreement ICC was necessary. As a subset was being double coded and the remaining 
sessions were to be rated by one coder single-measures was more appropriate than 
average-measures ICC. Finally, as the coders were not randomly sampled from the 
population a mixed effects model was chosen over a random model. Therefore, the 
inter-rater reliability for MI spirit was calculated using a two-way mixed, absolute 
agreement, single-measures ICC. The resulting ICC was in the fair range, ICC = .53 
(Cicchetti, 1994), indicating that coders had a fair degree of agreement but that there 
was some disagreement between coders. This result is comparable to reliability 
estimates achieved for MI spirit in other studies. For example, Gaume, Gmel and 
Daeppen (2008) achieved an ICC of .53 while Apodaca et al. (2013) report an ICC of 
.48. 
Due to the nature of the SMACS whereby one code (non-motivational client speech) 
accounted for the majority of client speech (87%) a measure of inter-coder agreement 
such as Cohen’s kappa (1960) or Krippendorf’s alpha (1970) is not advised as these 
indices are affected by skewed distributions of categories (Di Eugenio & Glass, 2004; 
Feinstein & Cicchetti, 1990). One statistic which has been developed to overcome this 
prevalence problem and is demonstrated to be superior for use with skewed data is 
Gwet’s (2008) AC1 statistic (Wongpakaran, Wongpakaran, Wedding, & Gwet, 2013). 
Gwet’s (2008) AC1 statistic was used to investigate the inter-rater reliability of the 
SMACS (see Table 6). The overall inter-rater reliability as calculated by Gwet’s AC1 
statistic was .89 indicating near perfect agreement (Landis & Koch, 1977). When 
considering the level of each code Gwet’s AC1 statistic of .95 (perfect agreement) was 
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achieved for non-motivational client speech, .45 (moderate agreement) was achieved 
for controlled motivation and a value of .32 (fair agreement) was reported for 
autonomous motivation. The lower reliability-estimates for autonomous and 
controlled motivation appeared to be due to difficulties in distinguishing between 
controlled and autonomous motivation in relation to ART adherence. Extensive 
coding meetings were held and further training was provided in an attempt to improve 
reliability. As the reliability was low the research supervisor checked all SMACS 
coding.    
Table 6 Inter-rater reliability using SMACS 
Variable AC1 
Percentage 
Agreement 
Overall .89 90.09 
Autonomous Motivation .32 32.81 
Controlled Motivation .45 31.19 
Non-motivational client speech .95 98.79 
   
Validity-testing of the SMACS 
The convergent validity of the SMACS was tested by correlating it with baseline 
results on the TSRQ (Williams et al., 2004) which is an established self-report 
measure of autonomous and controlled motivation.  Pearson’s product-moment 
correlation coefficients were used to explore the relationships between both 
autonomous and controlled motivation as measured by the SMACS and the 
autonomous and controlled motivation subscales on the TSRQ. There was no 
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relationship found between autonomous motivation as measured by the SMACS and 
the autonomous subscale of the TSRQ, r (60) = .07, p = .64, 95% BCa CI [-.42, .23]. 
There was no relationship found between controlled motivation as measured by the 
SMACS and the controlled subscale of the TSRQ, r (60) = .06, p = .69, 95% BCa CI 
[-.13, .43]. Consequently, the convergent validity of the SMACS was not established.  
Analysis procedure 
Data were analysed using IBM Statistical Package for the Social Sciences (SPSS) 
software version 21.0 (IBM, 2012). Alpha levels were set at p < .05 and all hypothesis 
testing was two-tailed to minimise the possibility of Type I errors. The data were 
screened for missing data and the normality of the data were tested. Pearson’s 
product-moment correlation coefficients were used to explore the associations 
between the continuous variables. Mediational analysis was used to investigate the 
proposed indirect effect of therapist use of MICO methods and MI spirit on ART 
adherence as mediated by client change talk. The mediational models were tested 
using the bootstrapping approach to mediation (Preacher & Hayes, 2004) which was 
carried out using the PROCESS macro for SPSS (Hayes, 2012). These analyses are 
described in more detail in the results chapter.   
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Chapter 3: Results 
Data screening  
Following the procedures outlined by Tabachnick and Fidell (2013) the data were 
screened prior to the main analyses being conducted. This screening involved 
checking the accuracy of the data by ensuring that the minimum and maximum values 
for each measure fell within expected ranges. 
Missing data 
The only missing data was with the week 1 and week 2 ART adherence data. One 
participant had missing adherence data across both week 1 and week 2, another had 
no adherence data for week 1 and two lacked adherence data for week 2. As this study 
is investigating the relationship between client and therapist speech and ART 
adherence change it was decided to omit these cases from the study (n = 4; 6.1%) 
rather than impute the missing data.      
Normality 
Normality of the variables relevant to study hypotheses was assessed by inspecting 
histograms with normal curves and calculating standardised skewness and kurtosis 
statistics (z-scores). Given the sample size (n = 62) variables with skewness and 
kurtosis z-scores which exceeded 2.58 (p < .01) were considered to be significantly 
non-normal (Field, 2013). All variables were found to be non-normally distributed 
(see Table 7). The adherence data (percentage of doses taken on time at week 1, week 
2 and week 12) was negatively skewed which was expected given the high level of 
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motivation to adhere to ART medication reported at baseline and the data reported in 
Goggin et al. (2013). MI spirit was also negatively skewed reflecting the high 
standard of the MI delivered. As the remaining data were derived from frequency 
counts the positively skewed distributions were expected (Atkins, Baldwin, Zheng, 
Gallop, & Neighbors, 2013).   
Table 7 Skewness & kurtosis z-scores 
Variable 
Skewness z-
scores 
Kurtosis z-
scores 
Week 1 percentage of doses taken on time  -4.48 1.25 
Week 2 percentage of doses taken on time -3.90 0.88 
Week 12 percentage of doses taken on time -3.00 -0.58 
MI Spirit -5.08 1.89 
Change Talk 7.30 3.38 
Sustain Talk 5.32 2.14 
MICO Responses 3.54 1.97 
Autonomous Motivation Talk 4.77 2.08 
Controlled Motivation Talk 12.18 5.56 
   
Transformations 
Transformations of the data were explored in an attempt to improve normality 
(Tabachnick & Fidell, 2013). As some of the variables were negatively skewed with 
most scores being higher up the range it was necessary to reflect the variable first 
before carrying out the transformations. This was achieved by finding the largest 
score in the distribution adding 1 and subtracting each score from this (Tabachnick & 
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Fidell, 2013). The square root (SQRT) transformation was applied to the data in the 
first instance (see Table 8). Skewness and kurtosis z-scores below 2.58 (p < .01) were 
only achieved for the adherence data, sustain talk, MICO responses and autonomous 
motivation talk. A log 10 transformation was carried out on the remaining variables; 
MI spirit, change talk and controlled motivation talk. This transformation was 
successful for all variables but one (MI spirit). Additional transformations (inverse, 
squared, cubed) were applied without success to MI spirit (see Table 8).   
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Table 8 Skewness & kurtosis z-scores for transformed variables 
 
Transformed Variable 
Skewness z-
scores 
Kurtosis z-
scores 
Sqrt Week 1 (% doses taken on time) 1.82 -1.18 
Sqrt Week 2 (% doses taken on time) 2.02 -1.32 
Sqrt Week 12 (% doses taken on time) 0.90 -1.27 
Sqrt MI Spirit 4.60 1.74 
Sqrt Change Talk 4.26 2.10 
Sqrt Sustain Talk 1.22 1.16 
Sqrt MICO Responses 1.55 1.06 
Sqrt Autonomous Motivation Talk -0.28 -0.65 
Sqrt Controlled Motivation Talk 4.55 2.83 
Log 10 MI Spirit 4.27 1.60 
Log 10 Change Talk 1.64 0.91 
Log 10 Controlled Motivation Talk -0.02 1.43 
Inverse MI Spirit -2.77 1.43 
MI Spirit squared -4.44 1.68 
MI Spirit cubed -3.78 1.50 
   
Univariate outliers 
An outlier is a case that has an extreme value on one variable (univariate) or a 
combined extreme score on two or more variables (multivariate) when compared with 
other observations within the dataset (Tabachnick & Fidell, 2013). Outliers can be a 
source of statistical bias (Field, 2013). Univariate outliers were identified by 
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inspecting the boxplots of both the raw and transformed data and noting any outliers 
identified. An inspection of z-scores was used to bolster and confirm the graphical 
identification of outliers. Three cases were identified across both methods of 
identifying outliers in the raw data but none were identified in the transformed data. 
The three cases were checked to ensure no errors were made in calculation or data 
entry. These cases were kept in the dataset as there was no theoretical bases for them 
to be removed or adjusted.  
Robust methods 
Alternative methods for dealing with non-normal data were explored seeing as a 
suitable transformation for MI spirit was not found and there was no justification to 
remove the outliers from the dataset. 
With the increasing computational power of statistical software there are now more 
options available with regards to alternative statistical tests which do not rely on the 
assumption of normally distributed data (Field, 2013). One such robust method is 
bootstrapping. This is a statistical method of resampling and replacement whereby 
smaller samples of the same size are repeatedly drawn from and replaced in the 
original sample thus generating a bootstrap distribution with the aim that repeated 
sampling allows for an estimation of the true population (Efron & Tibshirani, 1993). 
The bootstrap procedure is used to estimate standard errors and confidence intervals 
of parameters of the distribution such as odds ratios and correlation coefficients 
(Efron & Tibshirani, 1993). Where sophisticated software is available, a minimum of 
1,000 replications is advised to increase the chance of achieving confidence intervals 
which represent the population (Efron & Tibshirani, 1993). Bootstrapping methods 
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require fewer assumptions than traditional parametric tests (Hesterberg, Moore, 
Monaghan, Clipson, & Epstein, 2006). No assumptions about the population, 
normality of error terms or equal variance are made, therefore bootstrapping methods 
can be safely used with both parametric and non-parametric models (Efron & 
Tibshirani, 1993).  One of the main limitations of bootstrapping methods is the fact 
that if the initial sample is biased then the bootstrapping will just replicate those 
biases (Hesterberg et al., 2006). Bootstrapping methods are also sensitive to sample 
size and a sample of at least fifty participants is advised (Sideridis & Simos, 2010).  
Bootstrapping has been demonstrated to be a superior method for correcting for 
assumption violations (than transforming data) and controlling for Type I errors, 
particularly where the data is not normally distributed (Berkovits, Hancock, & Nevitt, 
2000; Delucchi & Bostrom, 2004; Russell & Dean, 2000).  Therefore, all analyses 
were conducted on the raw data with bootstrapping methods applied. As the data were 
skewed, the bootstrap bias-corrected accelerated (BCa) method (Efron, 1987) was 
used to control for the limitations of biases and sample size that are present in 
standard bootstrapping procedures. Confidence intervals were set at 95% and when 
interpreting these results a range that did not contain 0 denoted a significant effect at p 
< .05.  
Descriptive statistics 
Descriptive statistics for MI spirit, change talk, sustain talk, MICO responses, 
autonomous motivation talk, controlled motivation talk and ART adherence are 
presented in Table 9.  
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Following the recommendations given by Tabachnick and Fidell (2013) for reporting 
central tendency in skewed data the median and interquartile range are reported along 
with the mean and standard deviation.  
Table 9 Descriptive statistics of coding and adherence data 
 
Variable Median 
 
Interquartile 
Range 
 
 
Mean 
 
 
SD 
Week 1 (% doses taken)  96.43 71.43 – 100.00 84.35 22.67 
Week 2 (% doses taken) 100.00 76.79 – 100.00 86.28 25.71 
Week 12 (% doses taken) 89.27 70.23 – 99.18 78.17 27.36 
Week 1 (% doses taken on time)  85.71 62.50 – 100.00  76.05 29.85 
Week 2 (% doses taken on time) 89.29 57.14 – 100.00 74.25 33.49 
Week 12 (% doses taken on time) 78.57 53.00 – 95.21 69.42 29.38 
MI Spirit (1 – 5)  4.00 3.92 – 4.00 3.88 0.28 
Change Talk (count) 38.00 30.75 – 55.75 45.87 24.69 
Sustain Talk (count) 13.00 8.00 – 18.25 16.00 12.65 
MICO Responses (count) 62.50 48.00 – 76.00 63.95 22.07 
Autonomous Motivation Talk (count) 3.00 1.75 – 6.00 4.26 3.94 
Controlled Motivation Talk (count) 6.50 4.00 – 10.00 8.48 8.55 
     
Exploratory bivariate analysis 
Exploratory bivariate analyses were conducted to inform the interpretation of the 
hypothesis-driven analysis. The associations between therapist (MICO responses and 
MI spirit) and client (change talk and sustain talk) variables were explored using 
Pearson’s product-moment correlation coefficients. Pearson r values indicate the 
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magnitude and direction of a relationship. An r value of 0 indicates no relationship at 
all, a value of 1 indicates a perfect positive correlation, and a value of –1 indicates a 
perfect negative correlation. The strength of the relationship can be interpreted as 
small (r = .10), medium (r = .30), or large (r = .50) (Cohen, 1988). As the variables 
were skewed the bootstrap bias-corrected accelerated (BCa) method (Efron, 1987) 
was used to calculate 95% bootstrap confidence intervals. The number of bootstrap 
replications was set at 1,000.  
There was a significant strong positive correlation between MICO responses and both 
change talk and sustain talk (see Table 10). There was also a significant medium 
correlation observed between change talk and sustain talk. There was no relationship 
found between MI spirit and change talk, r (60) = .09, p = .47, 95% BCa CI [-.27, 
.44], sustain talk, r (60) = .02, p = .91, 95% BCa CI [-.26, .25] or MICO responses, r 
(60) = .01, p = .95, 95% BCa CI [-.32, .33].  
Table 10 Pearson product-moment correlation coefficients (r) between Change Talk, 
Sustain Talk, MICO Responses and MI Spirit 
 
Variable 
 
1 
 
2 
 
3 
 
4 
1. MICO Responses 
 
— 
   
2. MI Spirit 
.01 
[-.32, .33] 
 
— 
  
3. Change Talk 
. 66** 
[.36, .81] 
.09 
[-.27, .44] 
 
— 
 
4. Sustain Talk  
.57** 
[.34, .76] 
.02 
[-.26, .25] 
.41** 
[.05, .68] 
 
 — 
Note. BCa 95% confidence intervals are contained in parentheses below each r value.  
**p < .001 
80 
 
Pearson’s product-moment correlation coefficients were used to explore the 
relationships between both therapist variables (MICO responses and MI spirit) and 
client variables (change talk and sustain talk) and ART adherence (pre-MI session and 
post-MI session). BCa 95% confidence intervals were estimated. There were no 
significant associations found (see Table 11).  
Table 11 Pearson product-moment correlation coefficients (r) between ART 
adherence (week 1, 2) and Change Talk, Sustain Talk, MICO Responses and MI Spirit 
 
Variable 
 
Pre-MI session 
adherence  
Week 1 
 
Post-MI session 
adherence 
Week 2 
MICO Responses 
-.01 
[-.28, .26] 
.01 
[-.26, .27] 
MI Spirit 
.17 
[-.16, .43] 
.19 
[-.06, .41] 
Change Talk 
.03 
[-.23, .28] 
.07 
[-.13, .27] 
Sustain Talk  
.15 
[-.07, .33] 
.15 
[-.10, .33] 
Note. BCa 95% confidence intervals are contained in parentheses below each r value.  
 
Partial correlations were performed to explore the relationship between both therapist 
variables (MICO responses and MI spirit) and client variables (change talk and 
sustain talk) and ART adherence post-MI session (week 2) whilst controlling for pre-
MI session adherence levels (week 1). BCa 95% confidence intervals were estimated. 
After controlling for pre-MI session ART adherence (week 1) there were no 
associations found between post-MI session ART adherence (week 2) and MICO 
responses r (59) = .03, p = .848, 95% BCa CI [-.26, .36]; MI spirit r (59) = .11, p = 
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.397, 95% BCa CI [-.14, .38]; change talk r (59) = .06, p = .629, 95% BCa CI [-.14, 
.24]; or sustain talk r (59) = .07, p = .575, 95% BCa CI [-.24, .32].      
Hypothesis driven analysis 
Mediational analysis was used to investigate the proposed indirect effect of MICO 
responses and MI spirit on ART adherence as mediated by client change talk. The 
bootstrapping approach to mediation (Preacher & Hayes, 2004) was taken as unlike 
the widely used causal steps approach (Baron & Kenny, 1986) it does not rely on the 
assumption of normality in the distribution of the variables and therefore was more 
appropriate for the study data. Bootstrapping holds advantages over other mediational 
approaches as it is more statistically powerful and the risk of making Type I errors is 
reduced (MacKinnon, Lockwood, & Williams, 2004). Specifically bias-corrected 
bootstrapping has been found to be the most powerful bootstrapping method to use 
when carrying out mediational analyses (Hayes & Scharkow, 2013). A simple 
mediational model was employed to test hypothesis 1 and 2 (Preacher & Hayes, 
2004). Simple mediation allows for the addition of covariates to the model (Hayes, 
2012) which assists in removing potential sources of spurious relationships between 
the variables. To account for the temporal aspects of mediation analyses the pre-MI 
session ART adherence data (week 1) was entered as a covariate into both 
mediational models. 
Bootstrapping mediational analyses were carried out using the PROCESS macro 
V2.16 as an add-on to SPSS (Hayes, 2012). As recommended by Hayes (2009) 5,000 
bootstrapped replications were performed and the bias-corrected approach was used to 
estimate the 95% confidence intervals. 
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Hypothesis 1: client change talk during MI session 1 will mediate the relationship 
between therapist use of MICO methods in MI session 1 and post-session change in 
ART adherence 
A simple mediational model was employed to test hypothesis 1 which consisted of 
estimating the indirect effect of an independent variable X (MICO responses) on the 
dependent variable Y (ART adherence change) via an intervening or mediating 
variable M (change talk) (Preacher & Hayes, 2004). The independent variable (MICO 
responses) and the mediator variable (change talk) were both counts of speech during 
the MI session. The dependent variable (ART adherence change) consisted of the 
percentage of doses taken on time in the week following the MI therapy session. The 
covariate (pre-session ART adherence) consisted of the percentage of doses taken on 
time in the week preceding the MI session. See Table 9 for descriptive statistics of the 
variables entered into the model. Figure 4 shows the simple mediational model with 
the regression coefficients. 
 
Figure 4 Simple mediation model of hypothesis 1 
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The regression coefficients, standard errors and significance values for the simple 
mediation model as displayed in Figure 4 are shown in Table 12. As shown in both 
the table and figure there was a significant positive relationship between MICO 
responses and change talk (path a) however the association between change talk and 
ART adherence (path b) was non-significant. The direct effect of MICO responses 
and ART adherence (path c) was also found to be non-significant; b = -.035, p = .870, 
95% CI [-.460, .390]. The results indicate that higher levels of MICO responses were 
associated with higher levels of client change talk. No other associations were found. 
Table 12 Mediation model coefficients for MICO Responses on ART adherence via 
Change Talk 
  Consequent 
  M (Change Talk)  Y (ART adherence change) 
Antecedent  Coeff. SE p  Coeff. SE p 
X (MICO) a 0.733 .110 <.001 c’ -.035 .213 .870 
M (Change Talk)  — — — b .090 .190 .639 
constant i1 -3.364 9.716 <.001 i2 22.280 14.210 .122 
Note. SE= Standard error. i1 and i2 = regression intercepts. Coeff. = coefficient. 
     
The indirect effect of MICO responses (X) on ART adherence (Y) via change talk (M) 
was estimated. This is quantified as the product of the regression coefficient 
estimating path a (relationship between MICO responses and change talk) and the 
coefficient of path b (association between change talk and ART adherence). There 
was no significant indirect effect of MICO responses on ART adherence through 
change talk found; b = .066, 95% BCa CI [-.107, .381]. Therefore, the data are 
inconsistent with the hypothesis of mediation.  
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Hypothesis 2: client change talk during MI session 1 will mediate the relationship 
between MI spirit in MI session 1 and post-session change in ART adherence 
Hypothesis 2 was also explored using mediational analyses. A simple mediational 
model was developed which consisted of estimating the indirect effect of MI spirit 
(independent variable X) on ART adherence change (dependent variable Y) through 
the effect of change talk (mediating variable M). Again, pre-session ART adherence 
data (week 1) was entered as a covariate. The bias-corrected approach to 
bootstrapping was taken and 5,000 bootstrapped replications were carried out to 
estimate the 95% confidence intervals. The new variable in this model – MI spirit – 
was a global measure of the level of MI spirit demonstrated by the therapist during the 
session. Descriptive statistics for the variables in the model are shown in Table 9.  
The simple mediational model to investigate hypothesis 2 is shown in Figure 5, along 
with the regression coefficients from the analyses.   
Figure 5 Simple mediational model of hypothesis 2 
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The regression coefficients, standard errors and significance values for the simple 
mediation model depicted in Figure 5 are displayed in Table 13. There were no 
significant associations found between MI spirit and change talk (path a) or between 
change talk and ART adherence (path b). The direct effect of MI spirit and ART 
adherence (path c’) was also found to be non-significant; b = 10.201, p = .424, 95% 
CI [-15.133, 35.534].  
Table 13 Mediation model coefficients for MI Spirit on ART adherence via Change 
Talk 
  Consequent 
  M (Change Talk)  Y (ART adherence change) 
Antecedent  Coeff. SE p  Coeff. SE p 
X (MI Spirit) a 7.938 11.438 .490 c’ 10.201 12.656 .424 
M (Change Talk)  — — — b .059 .144 .683 
constant i1 14.110 43.899 .749 i2 -16.988 48.418 .728 
Note. SE= Standard error. i1 and i2 = regression intercepts. Coeff. = coefficient. 
 
The indirect effect of MI spirit (X) on ART adherence change (Y) via change talk (M) 
was estimated. There was no significant estimated indirect effect of MI spirit on ART 
adherence through change talk found; b = .466, 95% BCa CI [-1.942, 10.306]. Hence 
the findings shown no support for hypothesis 2.  
Hypothesis 3: higher levels of ART adherence will be more closely associated with 
naturally occurring autonomous motivation talk than controlled motivation talk 
expressed during MI session 1 
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Pearson’s product-moment correlation analyses were carried out to test the 
relationship between both autonomous and controlled motivation talk and percentage 
of doses taken before (week 1) and after the first MI session (week 2, week 12). As 
the data were skewed BCa 95% confidence intervals were estimated. Across the three 
time points for ART adherence data the correlation coefficients were larger for 
autonomous motivation talk than for controlled motivation talk (see Table 14). There 
was a medium significant positive correlation between autonomous motivation talk 
and ART adherence in the week following the MI session (week 2), r (60) = .28, 
p<.05, 95% BCa CI [.06, .45]. There were no other significant correlations observed.  
Table 14 Pearson product-moment correlation coefficients (r) between ART 
adherence (week 1, 2, 12) and Autonomous and Controlled Motivation Talk  
 
Variable 
 
Autonomous 
Motivation Talk 
 
Controlled 
Motivation Talk 
Week 1 (% of doses taken on time) 
.08 
[-.15, .27] 
-.01 
[-.29, .31] 
Week 2 (% of doses taken on time) 
.28* 
[.06, .45] 
-.10 
[-.31, .11] 
Week 12 (% of doses taken on time) 
.20 
[-.06, .39] 
.03 
[-.13, .23] 
Note: BCa 95% confidence intervals are contained in parentheses below each r value.  
*p<.05. 
 
Follow up tests for dependent correlations were carried out to investigate if the 
correlation coefficients were significantly different from one another. The correlation 
coefficients were converted to z-scores using Fischer’s transformation and established 
equations were applied to compute the asymptotic covariance of the estimates. Then 
an asymptotic z-test was performed (Lee & Preacher, 2013; Steiger, 1980).  
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The association between autonomous motivation talk and ART adherence after the MI 
session (week 2) was significantly larger than the association between controlled 
motivation talk and ART adherence at week 2; z = 2.37, two-tailed, p = .018. The 
association between autonomous motivation talk and ART adherence at week 1 was 
not significantly larger than the association between controlled motivation and week 1 
ART adherence data; z = 0.51, two-tailed, p = .61. The association between 
autonomous motivation talk and week 12 ART adherence data was also not 
significantly different from the relationship between controlled motivation and ART 
adherence at week 12; z = 1.03, two-tailed, p = .30. 
The fact that association between autonomous motivation talk and ART adherence 
after the MI session (week 2) was significantly larger than the association between 
controlled motivation talk and ART adherence at week 2 offers partial support for 
hypothesis 3. Higher levels of ART adherence were more closely associated with 
naturally occurring autonomous motivation talk than controlled motivation talk.   
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Chapter 4: Discussion 
In this final chapter, the aims of the study are revisited. The findings are summarised 
and discussed within the context of existing empirical studies and theoretical 
frameworks. The strengths and limitations of the study are considered and potential 
directions for future research are offered. Finally, the clinical implications of the study 
are outlined.  
Research aims 
The main aim of the study was to investigate MI mechanisms of change within the 
context of ART adherence in adults living with HIV. Based on the causal chain model 
of MI developed by Miller and Rose (2009) it was predicted that both therapist use of 
MICO methods and therapist MI spirit would have an indirect positive effect on 
improving ART adherence by eliciting client change talk. Therefore, it was 
hypothesised that MI spirit, MICO responses and client change talk would act as 
mechanisms of change for ART adherence.  
A secondary aim of the study was to explore the relationship between ART adherence 
and more fine-grained naturally occurring motivational speech than MI specifies. 
SDT proposes that motivation lies on a continuum from fully self-determined to non-
self-determined action with autonomous motivation being more self-determined than 
controlled motivation (Deci & Ryan, 2008). Autonomous motivation has been shown 
to have a stronger relationship with health related behaviours than controlled 
motivation does (Hagger et al., 2014). Autonomous motivation has also been shown 
to be associated with ART adherence (Kennedy et al., 2004). Autonomous motivation 
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is typically measured using self-report questionnaires however self-report measures 
can be unreliable measurement tools as they are subject to biases in memory, context 
and mood (Schwarz & Oyserman, 2001). The existing measures of autonomous and 
controlled motivation were developed using a deductive top-down approach to item 
generation. It is argued that an inductive bottom-up approach to the measurement of 
psychological constructs which considers the perspective of the participant is 
necessary to establish construct validity (Brod et al., 2009). This study aimed to 
measure autonomous and controlled motivation using an inductive approach through 
the observational method of coding naturally occurring speech and it is argued that 
this may be a more valid measurement process that using self-report measures. It was 
predicted that naturally occurring autonomous motivation talk was more likely to be 
related to ART adherence levels than controlled motivation talk.  
Overview of findings 
Three hypotheses were tested in the study and the findings for each hypothesis will be 
presented and discussed in turn.  
Hypothesis 1 
Client change talk during MI session 1 will mediate the relationship between therapist 
use of MICO methods in MI session 1 and post-session change in ART adherence 
The findings of the study were inconsistent with regards to the hypothesis that change 
talk mediates the relationship between therapist use of MICO methods and change in 
ART adherence. This contradicted previous MI studies investigating the technical 
pathway of the MI model. Pirlott et al. (2012) found evidence that client change talk 
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mediated the relationship between therapist use of MICO methods and change in fruit 
and vegetable consumption. However this study relied on difference scores 
(difference between fruit and vegetable intake at baseline and 1 year follow up) which 
are thought to be inherently unreliable (Edwards, 1994). The technical component of 
MI was also upheld in research by Moyers et al. (2009) who found an indirect effect 
of MICO responses on alcoholic drinks per week through client change talk. This 
study used multilevel modelling to control for baseline level of drinks per week. In 
contrast to the current study both studies which found evidence for the technical 
pathway demonstrated large changes in target behaviour. For example, in Moyers et 
al. (2009) the mean drinks per week pre-MI session was 76.3 and this had reduced to 
6.8 by week 5 (time-point used for mediation analysis) and Pirlott et al. (2012) 
reported that almost half of the sample had increased their fruit and vegetable intake 
by at least 50% following MI sessions.   
Similar to the current research study Vader et al. (2010) in a sample of heavy-drinking 
college students, did not find evidence that client change talk mediated the 
relationships between therapist use of MICO methods and drinking outcomes (using 
multilevel modelling) but did find an association between therapist use of MICO 
methods and client change talk. In contrast to Moyers et al. (2009) and Pirlott et al. 
(2012) the mean change in target behaviour was relatively small for example mean 
baseline drinks per week for the MI group was 16.05 and this had reduced to 12.43 by 
the 3 month follow up. This mirrors the current study where the change in ART 
adherence following the MI session was relatively small.  
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The current study provides some evidence in partial support of the technical pathway 
of the MI model in that there was a relationship found between therapist use of MICO 
methods and client change talk. Higher levels of MI consistent therapist responses 
were associated with higher levels of client change talk. These findings replicate other 
studies which have shown a positive relationship between therapist use of MICO 
methods and client change talk in the context of MI sessions targeting smoking 
behaviour (Catley et al., 2006) and alcohol use (Apodaca et al., 2013). Sequential 
analyses which offer additional support for the temporal nature of the mechanism 
have also found a stronger association for MICO responses eliciting client change talk 
than vice versa (Gaume, Gmel, Faouzi, & Daeppen, 2008; Moyers et al., 2007).  
The absence of a relationship between overall therapist use of MICO methods and 
outcome as observed in this study diverges from Moyers et al. (2009) who found a 
relationship between therapist use of MICO methods and fewer alcoholic drinks in a 
group of problem drinkers. Similar to the findings of the current study an absence of a 
direct relationship between overall therapist use of MICO methods and outcome has 
also been observed with partner aggression in a group of physically aggressive young 
adult college student couples (Woodin, Sotskova, & O’Leary, 2012). However, this 
study also explored each MICO method separately and found a relationship for one 
technique namely ratio of reflections to questions. The absence of a relationship 
between therapist use of MICO methods and ART adherence stands in contrast to the 
study carried out by Thrasher et al. (2006). They found an association between both 
ratio of reflections to questions and affirming statements and ART adherence levels in 
a sample of HIV positive patients in the United States, although they did not control 
for baseline adherence levels. It is possible that only certain MICO methods such as 
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ratio of reflections to questions may be related to change in ART adherence however 
the current study focused on an aggregate measure of MICO methods and did not 
explore relationships at the level of individual techniques in an effort to limit type I 
errors.  
The absence of a mediation effect was unexpected considering the results from 
existing process research studies as outlined above. One explanation for the null 
findings in the current study is the fact that the sample reported high levels of 
depressive symptoms and depression has been shown to be associated with poor 
adherence to ART (Langebeek et al., 2014). This is less likely to explain the findings 
in this case as participants achieved relatively high levels of pre-MI session ART 
adherence despite experiencing high levels of depressive symptoms. Another possible 
explanation was the lack of variability in the dependent variable. Both Moyers et al 
(2009) and Pirlott et al. (2012) observed large variability in the target behaviour 
before and after the MI intervention. The restricted range observed in change in ART 
adherence may have limited the effect size observed (Goodwin & Leech, 2006).  
Another possible contributor to the null findings in this study is that the dependent 
variable was only based on one session of MI. It is possible that MI may have a 
dosage effect. Pradier et al. (2003) found that ART adherence was superior for those 
who completed at least three sessions of MI in comparison to those who had just had 
one or two sessions. This is a possibility as both studies which found evidence in 
support of the mediated effect of the technical component (Moyers et al., 2009; Pirlott 
et al., 2012) were based on more than one session of MI, whereas the other study to 
fail to find evidence for the indirect effect of therapist use of MICO methods on 
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behaviour change via change talk was also based on only one session of MI (Vader et 
al., 2010).  
Another likely explanation for the null findings observed were the high levels of 
baseline motivation reported by participants. MI is an intervention which has been 
developed to target ambivalence and has been shown to be most effective for people 
who are experiencing low levels of motivation for behaviour change (Hettema & 
Hendricks, 2010). The sample in this study were highly motivated. Baseline 
motivation was not measured in the other studies outlined above thus comparisons 
cannot be made. However, it is unlikely that the sample in the current study would 
benefit from or require an intervention which targets motivation. Any low adherence 
observed in the sample was more likely to have related to a different aspect of the 
IMB model of ART adherence and an intervention targeting adherence-related 
information (adherence education training) or behaviour skills (using reminder 
devices) for those who were struggling to adhere to ART may have been more 
suitable.     
Hypothesis 2 
Client change talk during MI session 1 will mediate the relationship between therapist 
MI spirit in MI session 1 and post-session change in ART adherence 
There was no evidence found in support of the relational pathway of MI within the 
context of improving ART adherence levels; namely change talk was not found to 
mediate the relationship between MI spirit and ART adherence. In fact, there were no 
significant associations found between any of the variables both with and without 
controlling for baseline adherence. This result was in contrast to other research 
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studies. Pirlott et al. (2012)  found an indirect effect of MI spirit on daily fruit and 
vegetable consumption (without controlling for baseline intake) via client change talk 
in a group of firefighters. Catley et al. (2006) found a relationship between MI spirit 
and increased client change talk in a smoking cessation trial for African-American 
smokers. Grodensky et al. (2017) reported an association between MI spirit and fewer 
instances of unprotected anal/vaginal intercourse at 8-month follow up in a group of 
American adults attending a HIV clinic. Baseline rates of unprotected anal/vaginal 
intercourse do not appear to have been factored in to the analysis.   
The non-significant associations found when testing the relational pathway of the MI 
model have been noted in other studies. In a sample of people receiving medical 
treatment at an emergency department following the consumption of alcohol Apodaca 
et al. (2013) did not find a significant relationship between MI spirit and client change 
talk during an MI session targeting alcohol use. An absence of a relationship between 
MI spirit and outcome has been demonstrated for partner aggression in a group of 
physically aggressive college student couples (Woodin et al., 2012) and alcohol use 
outcomes in a group of hazardous alcohol drinkers attending the emergency 
department of a Swiss hospital (Gaume, Gmel, & Daeppen, 2008).   
The absence of a mediation effect was not anticipated and neither were the lack of 
statistically significant associations between variables. As with hypothesis 1 the null 
findings might be accounted for by the high levels of depressive symptoms in the 
sample or the possible dosage effect of MI may explain the lack of associations found. 
The absence of a relationship between client speech or therapist MI spirit and ART 
adherence change may also be explained by the scripted nature of the therapy 
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sessions. In an attempt to control for variation between therapists the MI was 
manualised and each therapy session followed the same general structure.  
Manualised MI has been associated with poorer outcomes when compared to non-
manualised MI (Hettema et al., 2005). The manualised nature of the session may have 
also led to reduced variability in therapist performance which is indicated by the high 
MI spirit scores observed across the sample. Measurement error may have also 
contributed to the research findings. The inter-rater reliability estimates for MI spirit 
although in line with other studies (Apodaca et al., 2013; Gaume, Gmel, & Daeppen, 
2008) are only fair and indicate considerable disagreement between raters which may 
represent measurement error. There was little variability in the scores for MI spirit 
with all the therapists achieving high scores. This may reflect a lack of sensitivity in 
the scale to detect difference in levels of MI spirit in therapists who are proficient in 
MI. A restricted range in both variables (MI spirit and ART adherence change) is a 
situation where low variability is most likely to influence a correlation (Goodwin & 
Leech, 2006). Consequently, the null findings between MI spirit and ART adherence 
may be explained by low variability observed in both variables.    
As with hypothesis 1 the most likely explanation for the null findings for hypothesis 2 
is the high levels of baseline motivation observed. MI is an intervention which aims to 
increase motivation to change a target behaviour and unsurprisingly it has been found 
to be most effective with those experiencing ambivalence or low motivation to change 
(Hettema & Hendricks, 2010). Therefore, the high baseline motivation levels limit the 
possibility of MI producing an effect. Another ceiling effect which may explain the 
null findings for both hypotheses is the high level of adherence to ART observed prior 
to the delivery of the MI session. High levels of ART adherence left little opportunity 
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for improvement in ART adherence and would have reduced the chances of finding a 
relationship between the proposed mechanisms of change and ART adherence.  
Hypothesis 3 
Higher levels of ART adherence will be more closely associated with naturally 
occurring autonomous motivation talk than controlled motivation talk expressed 
during MI session 1 
The results of this study offer tentative support for hypothesis 3 as there was a 
significant medium strength relationship found between autonomous motivation talk 
and ART adherence in the week following the MI session (week 2) and there was 
non-significant associations found between controlled motivation talk and percentage 
of ART doses taken on time. The association between autonomous motivation and 
ART adherence at week 2 was significantly larger than the association between 
controlled motivation and ART adherence at the same time-point. These results are in 
line with previous research which has shown that autonomous motivation has a larger 
effect on health behaviour outcomes than controlled motivation does (Hagger et al., 
2014) and that autonomous motivation is related to successful long-term medication 
adherence (Williams et al., 1998). The results also offer support for research carried 
out by Kennedy et al. (2004) which found a small association between autonomous 
motivation and doses of ART taken on time. However, these results must be 
interpreted cautiously as there were no significant relationships found between either 
autonomous or controlled motivation and ART adherence at weeks 1 and 12 and had 
Bonferroni correction been applied the results would no longer be significant.  
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The absence of relationships found between autonomous motivation and ART 
adherence at weeks 1 and 12 may be explained by limitations in the validity and 
reliability of the SMACS as a measurement tool. Convergent validity could not be 
established as there was no associations found between scores on the SMACS and an 
established measure of autonomous and controlled motivation namely the TSRQ 
(Williams et al., 2004). The reliability estimates of the SMACS at the level of 
autonomous motivation talk and controlled motivation talk were fair and moderate 
respectively.  
This study is the first to measure naturally occurring within-session autonomous and 
controlled motivational talk. Previous studies which have related autonomous and 
controlled motivation to behaviour outcome have relied on self-report measures such 
as the TSRQ (Williams et al., 2004) or the Behavioural Regulation In Exercise 
Questionnaire (Mullan et al., 1997). Although the validity and reliability of the 
SMACS may be limited in the current study it is promising that it detected a medium 
effect size in the relationship between autonomous motivation and ART adherence 
given a previous study using the TSRQ was only able to find a small effect (r = .15) 
between these two variables (Kennedy et al., 2004). The development of the SMACS 
and its use within this study offers encouragement for future research to explore the 
measurement of autonomous and controlled motivation within the context of naturally 
occurring speech.   
Limitations 
There are several limitations to the current study which must be taken into 
consideration when interpreting the findings.  
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Research design 
This study employed a predominantly cross-sectional design whereby there was no 
manipulation of variables. The session coding data was measured at one-time point. 
However, ART adherence was measured at different time-points across the study. 
Cross-sectional designs represent an economical and time efficient way to collect 
research data. The data is collected at a specific point in time allowing for the tracking 
of patterns in the data which can then be used to build evidence in support of 
theoretical models (Howitt & Cramer, 2011). However cross-sectional designs are 
limited by the fact that they cannot be used to establish causality as they do not allow 
for the manipulation of the mechanisms (Tabachnick & Fidell, 2013). There have 
been some process research studies within MI which have taken an experimental 
approach. Miller et al. (1993) randomly assigned participants to counselling in line 
with the principles of MI and directive-confrontational counselling before coding  
therapist behaviours.  Glynn and Moyers (2010) manipulated the intervention offered 
within-session by instructing the therapist to alternate between delivering MI and a 
non-MI behaviour change intervention (functional analysis) every 12 minutes. 
Finally, a recent study randomised therapists to two types of MI training one of which 
emphasised eliciting and selectively reinforcing client change talk (Moyers, Houck, 
Glynn, Hallgren, & Manuel, 2017). As this study was a secondary data analysis it was 
not possible to influence the planning of the design of the study. 
Cross-sectional designs do not account for the timeline of change. Kazdin (2007) 
points out that many process research studies use language which implies that a 
timeline has been established, for example that therapist use of MICO methods 
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precedes or predicts client change talk. However, it is argued that the timeline of 
change can only be truly established by building it in to the research design through 
the use of experimental approaches and multiple assessments of proposed 
mechanisms and outcomes throughout the treatment (Kazdin & Nock, 2003). It is 
possible to examine the temporal changes within a session through sequential analysis  
(e.g., Gaume, Gmel, Faouzi, et al., 2008; Moyers et al., 2007).  As this study was the 
first test of the technical and relational pathways within the context of ART adherence 
a less-resource intensive method than sequential analysis is advised as a first step to 
establish promising candidates for the MI model in a new population  (Miller & 
Moyers, 2015).  
Another limitation of the design of the study is that it is vulnerable to the risk of 
reverse causation which can limit the internal validity of the study (Elliott, 2010).  
Correlational studies which show a relationship between x and y usually assume a 
direction namely that x causes y, or in the case of this study that therapist use of 
MICO methods increases client change talk. However reverse causation where y 
causes x or client change talk increases therapist use of MICO methods is also 
possible. Previous sequential analyses of therapist and client exchanges during MI 
sessions suggest that therapist use of MICO methods elicits client change talk more 
strongly than client change talk elicits therapist use of MICO methods (Gaume, Gmel, 
Faouzi, et al., 2008; Moyers et al., 2007). This temporal evidence reduces the risk of 
reverse causation affecting the finding in this study that higher levels of therapist use 
of MICO methods were associated with higher levels of client change talk.  
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It is worth noting that although the research design may limit some of the conclusions 
that can be drawn, this research study has been modelled on a number of other key 
process research studies within the MI field such as Moyers et al. (2009) and Pirlott et 
al. (2012). Findings from process research studies which employ a cross-sectional 
design can be combined with experimental process studies (e.g., Glynn & Moyers, 
2010; Miller et al., 1993; Moyers et al., 2017) to demonstrate that a variable does in 
fact act as a mechanisms of change (Nock, 2007).  
Methodological issues 
The internal validity of the study is impacted by the fact that potential extraneous 
variables such as demographic or clinical information were not taken into 
consideration as part of the analysis of the study. It is possible that variables such as 
levels of depression, problems with substance misuse and the side effects of ART 
could have had an impact on the outcome of the study as these factors have been 
shown to be associated with ART adherence (Langebeek et al., 2014) and to be 
moderating variables in the IMB model of ART adherence (Fisher et al., 2008). These 
patient-level factors of adherence were not factored into the analyses as the addition 
of potential covariates or moderators would have required a larger sample which was 
not possible given the time constraints of the project. It is also possible that 
demographic information such as ethnicity may have affected the internal validity of 
the study. MI has been shown to have larger effects in ethnic minority populations in 
comparison to non-minority white populations (Hettema et al., 2005) although not 
necessarily African-Americans (Lundahl et al., 2010). To limit both type I and type II 
errors being made it was decided to limit the study to variables which have been 
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shown to be associated with the clinical MI model (Miller & Rose, 2009). Given the 
weak univariate relationships observed it is unlikely that controlling for the above 
variables would have resulted in significant relationships between the hypothesis-
driven variables.  
This research study is vulnerable to non-response bias whereby characteristics of the 
participants who consent to take part in the study are different from those who refuse 
to take part which can result in a sample that is not representative of the population 
under study (Mann, 2003). In the original RCT 31% (n = 97) of eligible participants 
declined to take part in the study and the most common reasons for refusal were being 
too busy, having a lack of interest in research or planning to move out of the 
catchment area of the study (Goggin et al., 2013). It is possible that non-response bias 
may affect the external validity of this study and must be taken into consideration 
when interpreting the findings.  
It is possible that the varying length of the sessions and the natural verbosity of the 
therapist or client may have potential confounding effects among behaviour count 
variables for coding data (Holsclaw et al., 2015). The longer the session or certainly 
the more talkative the therapist or client the greater the chance of the relevant coding 
variables (change talk, MICO responses, autonomous and controlled motivation talk) 
being observed thus increasing the likelihood of a type I error being made (Holsclaw 
et al., 2015). It is possible that the positive association found between MICO 
responses and change talk may be influenced by the length of the session. The fact 
that MI spirit – a global measure and therefore not as influenced by session length – 
and change talk were found to be unrelated makes it more likely that session length 
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may have acted as a potential confounding variable. The potential confounding nature 
of session length and verbosity of speech during the session must be held in mind 
when interpreting the results of the study.    
Another factor relating to the external validity of the study was the fact the therapists 
delivered the MI session according to a semi-structured script whereby each therapist 
had a list of questions or topics that they were required to cover during the session. 
Each session included in the current study broadly followed the same structure. The 
session commenced with a recap of the previous meeting, clarification whether the 
participant had read the ART education information given to them, review of MEMS 
data and a check of what were the positive and negatives that the participant had 
noticed due to taking the medication. Participants were then asked to identify any 
personal barriers or facilitators to ART adherence. The participants were asked to rate 
on a scale from 1 – 10 the level of importance and confidence they felt in relation to 
their ART adherence. Follow up questions were asked relating to where they placed 
themselves on the scale. The therapist then presented a list of values and asked the 
participants to pick their top two from the list. Participants were also invited to choose 
a value that was not on the list. Participants were then invited to think about how their 
values linked to their ART adherence. Finally, the session ended with the client being 
invited to set an adherence goal which would be followed up at the next session. An 
intervention script or protocol was deemed necessary to ensure that comparable MI 
treatment was delivered across the RCT. However, review studies have shown that 
manualised MI is less effective than non-manual guided MI (Hettema et al., 2005) 
particularly when compared to treatment as usual (Lundahl et al., 2010). It is argued 
that the reduction in responsiveness and flexibility that can accompany the delivery of 
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protocol driven MI interventions can result in increased resistance and sustain talk 
making behaviour change less likely (Amrhein et al., 2003) .  
Another limitation is that outcome adherence rates used in the study are only based on 
one session of MI and it is possible that one session might not have been sufficient to 
positively influence ART adherence. Much of the MI process research has been 
carried out with substance misuse. Meta-analytic research has shown that one session 
was the minimum effective dose to reduce alcohol use whereas studies showing an 
effect of MI for target behaviours associated with diet and exercise and medication 
adherence consisted of between four and eleven MI sessions (VanBuskirk & 
Wetherell, 2014). Pradier at al (2003) found that ART adherence was significantly 
higher for the participants who completed three sessions of MI compared to those that 
only completed one or two sessions.  
Use of historical data 
One key limitation of the study is that the data for the original RCT was collected 
between December 2004 and August 2009 (Goggin et al., 2013). This is important to 
factor in when considering the clinical implications of this study. At the time of the 
RCT the guidelines for prescribing ART advised that ART was only recommended 
for people who were displaying clinical symptoms of HIV or had a CD4 count of 
≤200 cells/mm3, and ART was to be considered on an individual basis with CD4 
count between 200 and 350 cells/mm3 for those who were asymptomatic (Hammer et 
al., 2006; Yeni et al., 2004). Since 2015 it is now recommended that all people living 
with HIV should be prescribed ART regardless of CD4 count or viral load (World 
Health Organization, 2016). This is an important change as now there is likely to be 
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more variation in HIV-related indices and thus potentially adherence motivation 
among those who are prescribed ART than was observed in the current sample. For 
example, many of the people taking part in the study were experiencing negative 
effects of the disease such as symptoms of HIV or low CD4 counts which may have 
increased their levels of motivation to adhere to ART. This is in contrast to the present 
where many people being prescribed ART may have healthy CD4 counts and be 
symptom free and thus may be less motivated to adhere to ART.  
Measurement 
Measurement error is a common methodological issue which applies to all 
psychotherapy process research (Hill & Lambert, 2004). Both process measurement 
tools used in this study (MISC 2.5 and SMACS) have certain limitations which must 
be considered when interpreting the results. 
For the MISC 2.5 one potential source of measurement error is the mediocre levels of 
inter-rater reliability observed for MI spirit. The ICC between the main coder and the 
second coder was .53 which according to the criterion guidelines (Cicchetti, 1994) 
represents a fair level of inter-rater reliability. The ICC results suggests that there was 
some disagreement in coding between raters and this disagreement could represent 
measurement error. Consequently, it is possible that the null findings observed when 
testing hypothesis two may be partially explained by measurement error. Existing 
process research which has tested MI spirit used earlier versions of the MISC to 
measure MI spirit and report inter-rater reliability statistics ranging from fair to 
excellent. Catley et al. (2006) report an ICC value of .79 for MI spirit in the context of 
MI sessions targeting smoking behaviour, Gaume, Gmel and Daeppen (2008) 
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achieved an ICC of .53 while Apodaca et al. (2013) report an ICC of .48 with both 
studies targeting alcohol use.  
The lack of variability observed in the scores for MI spirit might indicate that the 
global rating scale of the MISC 2.5 is not sensitive enough for use with therapists who 
adhere correctly to the MI model. The initial items on the scale were redundant with 
all therapists scoring at least 3 which may reflect a lack of sensitivity in the scale to 
detect difference in levels of MI spirit in proficient MI therapists. This may represent 
a measurement limitation of the MISC 2.5.   
The parsing of the transcripts is another area of potential measurement error. The 
MISC 2.5 manual advises that coding of a session should not be carried out by the 
same person who parsed the session (Houck et al., 2010). Moyers and Martin (2006) 
found that simultaneously parsing and coding a transcript resulted in difficulties in 
assessing reliability. It is suggested to use different coders for the parsing and coding 
passes of the MISC 2.5 to avoid a bias in parsing. Due to the nature of the research 
project and limited resources it was necessary for the author to carry out both the 
parsing and coding for all MI sessions. In an attempt to reduce the risk of 
measurement error in the parsing process the transcripts were parsed separate to the 
coding framework being applied. Any parsing queries were resolved by the research 
supervisor.  
The final potential source of measurement error was the MISC 2.5 coding training. 
Dobber et al. (2015) recommends at least 35 hours to reduce risk of coding bias and 
thus reduce measurement error. Due to limited time, it was only possible to spend 15 
hours training the second coder for the purposes of inter-rater reliability. In retrospect, 
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this training was limited by the fact that more time was dedicated to the behavioural 
coding rather than the global coding aspect of the tool. This occurred as the 
behavioural coding section of the manual is more extensive and complex than the 
relatively straightforward global coding requirement.  
Although it was not possible given the scope of the project, reliability of the MISC 
2.5 would have been improved by having as many coders as possible code the data 
and this would have helped to limit any potential bias in the data (Hill and Lambert, 
2004). As the main coder achieved an almost perfect level of fidelity to the gold 
standard transcripts during the training phase and the supervisor checked coding for 
one session out of every five to prevent coding drift, it is hoped that the measurement 
bias in the data is minimal.   
As the SMACS is a new tool which has been developed specifically for this study to 
measure autonomous and controlled motivational talk within an MI session it is 
important to consider its limitations as a measurement tool. The SMACS was low on 
convergent validity as there was no association found between baseline scores on an 
established measure of autonomous and controlled motivation (TSRQ; Williams et al., 
2004) and the amount of autonomous and controlled motivational speech expressed 
during the MI therapy session. This absence of an association may however be 
explained by measurement error present within the TSRQ. Self-report measures are 
vulnerable to certain biases such as socially desirable responding whereby on 
questionnaires people tend to present a favourable image of themselves which can 
lead to measurement error and limit results (Crowne & Marlowe, 1960). 
Questionnaires are also subject to demand characteristics whereby the participant is 
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influenced by what they anticipate the researcher might be expecting to find and thus 
may bias answers in response (Orne, 1962). The absence of a relationship between 
autonomous and controlled motivation as measured by the SMACS and the TSRQ 
may also be explained by limitations of the framework of SDT within the context of 
ART adherence. Much of our existing knowledge is built on information gathered 
using measures which have been grounded in the theoretical conception of 
autonomous and controlled motivation. The perspective of the participant or patient 
has been largely absent. One study which aimed to capture the patient’s experience 
found that participants’ implicit categorisations of autonomous and controlled 
motivations for adhering to ART as measured using multidimensional scaling, did not 
correspond to theoretical definitions or researcher and clinician understanding of these 
constructs (Houston et al., 2012).  
The reliability of the SMACS is also a limitation of the study. Overall a near perfect 
level of inter-rater reliability was achieved (.89). However, when considering the 
reliability at the level of individual codes reliability for autonomous motivation was 
fair (.32) and was moderate for controlled motivation (.45). Despite using Gwet’s AC1 
formula it is difficult to establish high levels of reliability when the prevalence of a 
code is low. At times, it was difficult to conceptually distinguish between controlled 
and autonomous motivational reasons for medication adherence as it was not always 
possible to determine if a behaviour was valued by the person. Due to the low inter-
rater reliability estimates achieved, all SDT coding was reviewed by the research 
supervisor who is an expert in motivational research but there continued to be 
ambiguity around the coding of adherence motivation as autonomous or controlled.  
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Ceiling effect 
The most likely explanation for the null findings in the study are the high levels of 
baseline motivation observed along with the relatively high levels of pre-MI session 
ART adherence.   
A high level of baseline motivation to adhere to ART was observed in the original 
RCT (Goggin et al., 2013). In the current study attempts were made to minimise the 
influence of high levels of baseline motivation by selecting a subsample which 
reported the lowest levels of motivation. However, this subsample was still reporting 
high levels of motivation with an average motivation level of 90%. The lowest level 
of motivation to adhere was 50% and this was only reported by one participant. Four 
participants reported 100% motivation to adhere while the rest of the sample (n = 57) 
fell in-between. The sample in this study was low on ambivalence to adhere to ART. 
It has been demonstrated that MI is most effective for people who are experiencing 
ambivalence or low levels of motivation to change the target behaviour (Hettema & 
Hendricks, 2010). In fact, MI was designed to help resolve ambivalence (Miller & 
Rollnick, 2012). It is unlikely that a significant proportion of non-adherence observed 
within the study was related to a lack of motivation. An intervention targeting 
motivation, therefore, was unlikely to have produced an effect, as was observed in the 
original RCT where no effect was found for MI (Goggin et al., 2013). It is possible 
that the adherence barriers for those not achieving 100% adherence were not related 
to the motivation aspect of the IMB model of ART adherence (Fisher et al., 2008).  
There was a relatively high level of ART adherence (median of 86% of doses taken 
on time) observed prior to the MI session with 65% of the sample achieving at least 
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79% of prescribed doses taken on time and 39% of participants taking all doses on 
time. When adherence is broadened out to include percentage of doses taken 
adherence rates increase to a median of 97% of doses taken with 74% of the sample 
achieving at least 79% adherence and 50% of the sample achieving perfect adherence. 
This is in contrast to other studies such as Thrasher et al. (2006) who report mean 
baseline adherence of 56% of doses taken, Ingersoll et al. (2011) who observed mean 
baseline adherence of 58% of doses taken and DiIorio et al. (2008) report a mean 
baseline level of 58% of ART doses taken on time. In a systematic review of ART 
adherence interventions Amico et al. (2006) found that interventions which only 
targeted people with low adherence levels demonstrated stronger effects that those 
targeting groups with varied baseline adherence levels. High pre-MI session 
adherence levels left little room for improvement in adherence in the study and this 
would have reduced the likelihood of finding a relationship between any of the 
proposed variables and ART adherence (Goodwin & Leech, 2006). 
Strengths 
Sample size 
The time intensive nature of the transcription and coding process meant that within 
the time frame of the project it was not possible to reach the targeted sample size of n 
= 75 as recommended by the power calculation. However, the sample size of the 
current study (n = 62) is larger than the sample size of the other published MI process 
research studies within the context of HIV-related behaviour change (Grodensky et 
al., 2017; Thrasher et al., 2006) and process studies with other targeted behaviours 
such as increased fruit and vegetable intake (Pirlott et al., 2012) and reduced alcohol 
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consumption (Glynn & Moyers, 2010; Miller et al., 1993). It is unlikely that a sample 
size of 75 would have resulted in significant findings given the small effect sizes 
observed for the mediational analyses.  
Measurement 
The use of the MISC 2.5 is a strength of this research study as many process research 
studies use earlier versions of the MISC which have limitations compared to the 
MISC 2.5. The MISC 2.5 combines features from two existing MI process tools; the 
MISC 2.1 and the SCOPE in an attempt to create a more valid tool which aims to 
capture the subtleties of both client and therapist language. The MISC 2.5 attempts to 
improve on the validity and reliability of earlier process tools by moving from a 7-
point to a 5-point Likert-type scale for the global measures and dropping the strength 
ratings from client behaviour counts (Houck et al., 2010). The MISC 2.5 is an 
established measure which has been developed by experts within the field of MI 
process research and consequently possesses both content and face validity. The 
researcher also liaised with the authors of the manual to obtain gold standard coded 
transcripts for the purposes of training.  
The SMACS possesses content validity as it was generated by combining both an 
inductive and deductive approach to the development of the measurement tool. SDT 
literature was reviewed and existing measures of autonomous and controlled 
motivation were consulted when developing the coding manual. Excluded MI 
sessions were used to develop examples for each coding category. The manual 
underwent numerous reiterations through regular consultation with an expert in HIV-
related behaviour change. The manual was further refined through a consultation 
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process with people living with HIV currently taking ART. In contrast to scale 
development using classical test theory where items are dropped if they do not load 
sufficiently on a factor or load equally across one or more factors, the SMACS 
requires the coding of all incidents of autonomous and controlled motivation. 
Therefore, it is possible that the SMACS is a more valid tool than questionnaires such 
as the TSRQ (Williams et al., 2004) which have been developed using classical test 
theory methods.  The content validity of the SMACS could, potentially, have been 
further improved by consulting with experts in the field of SDT such as Edward L. 
Deci and Richard Ryan.  
The use of the MEMS cap to collect ART adherence data is one of the strengths in 
this study. Electronic pill monitoring tools such as the MEMS cap are currently 
recognised as the gold standard for monitoring medication adherence (Vrijens et al., 
2014) and have been shown to be strongly associated with viral load when compared 
to other methods of monitoring ART adherence (Farley et al., 2003; Müller et al., 
2008). Particularly in relation to the SDT aspect of this study, using a MEMS cap 
improves on the Kennedy et al. (2004) study which relied on self-report data alone as 
a measure ART adherence.  
Robust methods 
The use of robust methods is one of the strengths of this study. As behavioural coding 
data involves frequency counts it is known to often violate the assumption of 
normally distributed data and the data is typically skewed (Holsclaw et al., 2015) as it 
was in this study. Bootstrapping methods have been demonstrated to be superior than 
transforming data when correcting for non-normally distributed data and controlling 
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for Type I errors (Berkovits et al., 2000; Delucchi & Bostrom, 2004; Russell & Dean, 
2000).  
Controlling for pre-session adherence.  
One of the key strengths of this study is the approach taken to the measurement of 
change in the target behaviour. This study improves on the two existing process 
research studies in the context of HIV (Grodensky et al., 2017; Thrasher et al., 2006) 
in its approach to measuring change in the target behaviour. Thrasher et al. (2006) 
calculated ART adherence change as the difference in scores between post-MI session 
adherence and pre-MI session adherence. The use of difference scores as a measure of 
outcome change is considered to be fundamentally unreliable (Edwards, 1994). It 
would appear that Grodensky et al. (2017) did not factor baseline rates of unprotected 
anal/vaginal intercourse in to the analysis either through use of difference scores or 
building it in to the statistical model. In the current study pre-session MI adherence 
levels are built in to the mediational model as a covariate and controlled for during 
partial correlation analyses. This approach is recommended over the use of difference 
scores (Edwards, 1994).  
Generalisability 
Selecting a subsample of less motivated participants ran the risk of reducing the 
external validity of the study. There is evidence however, that in reality the sample in 
this study is representative of the population of people living with HIV in North 
America with MSM and African-Americans being disproportionally affected by HIV 
(Centers for Disease Control and Prevention, 2015). This sample is somewhat 
representative of adults living with HIV in the UK as an estimated 69% are men and 
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MSM are most affected (Kirwan et al., 2016). The sample is unrepresentative with 
regards to ethnicity as in the UK the majority of MSM with a HIV diagnosis are of 
white ethnicity and the other group that is disproportionally affected by HIV are 
people of Black African ethnicity (Kirwan et al., 2016).   
The generalisability of the study is limited by the changes that have occurred in the 
guidelines for ART adherence. At the time of the original RCT the guidelines 
suggested that ART was not recommended for those who were asymptomatic and had 
a CD4 count >350 cells/mm3 (Hammer et al., 2006; Yeni et al., 2004). Since 2015 it is 
now recommended ART should be prescribed for all people living with HIV 
regardless of CD4 count or viral load (World Health Organization, 2016). 
Consequently, the sample in this study might not be fully representative of the current 
population of people living with HIV who are prescribed ART.  
Another factor limiting the generalisability of the findings was the high levels of ART 
adherence observed prior to the delivery of the MI session. Half of the sample were 
taking 100% of their prescribed doses while 39% were taking all their doses on time. 
The mean prescribed doses taken was 84% which is higher than other studies where 
prior to the delivery of MI means of 56% (Thrasher et al., 2006) and 58% (Ingersoll et 
al., 2011) of prescribed doses taken were reported. In this study, prior to receiving MI, 
71% of the sample were achieving mean adherence rates of at least 90% of doses 
taken and this is higher than the global rate of 62% of ART user achieving adherence 
rates of at least 90% (Ortego et al., 2011). It could be argued that many of the 
participants in this study were receiving an intervention for which they had no need. 
This is unlikely to reflect real-world situations where limited resources can mean that 
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potentially adherence improving interventions such as MI would only be offered to 
those with adherence rates of less than 90% of prescribed doses taken.   
Finally, the external validity of this study is potentially further limited by the delivery 
of the MI. The therapy sessions were audio-recorded and the fidelity of the therapists 
to the MI model was being monitored throughout the study. The therapists were also 
required to follow a semi-structured MI protocol or script. This monitoring process 
and the use of a therapy protocol is not reflective of usual clinical practice and may 
have meant that the therapists were less responsive or flexible. It was observed during 
the coding of sessions that at times therapists did not respond sensitively to 
participants’ distress and instead prioritised items on their MI agenda. It is possible 
that this may have impacted on the therapeutic alliance as participants may not have 
felt listened to by the therapist.  
Research implications 
Before any conclusions can be drawn about the technical and relational components 
of the MI model (Miller & Rose, 2009) within the context of ART adherence it is 
necessary to test the relationship between therapist use of MICO methods, MI spirit, 
client change talk and ART adherence in a group of people living with HIV who are 
experiencing low motivation to adhere and low baseline adherence rates. It is 
acknowledged that therapist use of MICO methods is a very broad category and future 
research might focus on exploring the association between different types of MICO 
responses and client change talk. For example, one study has found that affirming 
statements made by the therapist is the only MICO response which both increased 
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change talk and decreased sustain talk in the context of reducing hazardous drinking 
in a student population (Apodaca et al., 2016).  
Once evidence for both the technical and relational components has been found then 
future MI process research studies within the context of ART adherence should focus 
on sequential analysis to address the temporality limitation of correlational designs. 
Sequential analysis allows for an examination of the transitional probabilities of 
therapist use of MICO methods being followed by change talk and sustain talk. Future 
research might also make use of experimental methodologies to further bolster the 
evidence base and thus ensure all criteria required to establish a variable as a 
mechanism of change are met (Kazdin & Nock, 2003). Additional aspects of the 
relational pathway such as therapist empathy and alternative MI model components 
such as MI training within the context of ART adherence could also be investigated in 
future studies. 
This study provides tentative support for the use of an SDT informed motivational 
language coding system to measure autonomous and controlled motivation speech 
within the context of ART adherence. Future work on the development and 
refinement of the SMACS needs to be conducted. Additional research needs to be 
carried out to establish the reliability of the measure which may result in further 
modifications of the existing manual. Future research might also focus on extending 
the SMACS to include other target behaviours resulting in a more generic instrument 
which would be suitable for use across a variety of populations and settings. The 
refinement and extension of the SMACS could allow for a more nuanced 
understanding of naturally occurring motivational speech than is currently provided 
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by existing MI process tools which may further add to the understanding of how MI 
works. Although it should be acknowledged that SDT might need further refinement 
and exploration within the context of ART adherence which might allow the 
constructs of autonomous and controlled motivation to be measured more reliably and 
validly.  
Finally, this study provides tentative evidence to suggest a relationship between 
autonomous motivation and targeted behaviour outcome in this case ART adherence. 
Given the null findings also observed, replication of the study is needed before any 
substantive claims can be made. Future process research might explore the 
relationship between autonomous motivation and other behaviour change outcomes 
such as substance use, smoking, or exercise.  
Clinical implications 
One of the clinical implications of this study is a reminder to consider the 
characteristics of the population being targeted with an MI based ART adherence 
intervention. Medication adherence is a complex psychological process and 
motivation is only one facet of ART adherence as outlined by the IMB model (Fisher 
et al., 2008). MI is unlikely to be helpful for people who already possess high levels 
of motivation to adhere to ART.  For these people motivation is unlikely to be a 
barrier to their ART adherence and an alternative intervention targeting a different 
aspect of this multifaceted process might be more useful. For example, the 
information aspect of the IMB model may be targeted with medication adherence 
training while adherence-related behaviour skills may be developed through the use of 
reminder devices and behaviour skills training. It is important that barriers to 
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adherence are identified and formulated during the assessment period to ensure the 
intervention offered targets the appropriate aspect of the IMB model of ART 
adherence. An ART adherence intervention based on a formulation and targeting the 
individual factors underlying the problems in ART adherence is likely to be more 
effective than offering a standardised treatment protocol focussed predominately on 
enhancing motivation to change.   
The development and refinement of the SMACS, alongside its extension to other 
target behaviours, could result in a more nuanced understanding of client change talk, 
specifically regarding autonomous and controlled motivational speech. Understanding 
these potential mechanisms may facilitate further understanding of how MI works and 
may lead to enhancements in MI. For example, should the link between autonomous 
motivation and ART adherence be substantiated this could warrant the extension of 
MI to include eliciting and selectively reinforcing autonomous reasons for making a 
behaviour change. This could be easily incorporated into the framework of MI 
therapist strategies as there are already MI questions and techniques which encourage 
making a connection between personal values or goals and the targeted behaviour for 
change. Such an approach would be consistent with current directions within the field 
of MI where the focus is now on selectively responding to and thus influencing client 
change language within the MI session (Moyers et al., 2017).  
Conclusion 
The most likely explanation for the null findings relating to the MI model is the high 
baseline motivation and high levels of pre-MI session ART adherence which meant 
that there was little opportunity to show evidence of change, and therefore little 
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opportunity to show mediation. Findings from this study suggest that the SMACS 
may provide the basis for a more useful tool for measuring fine-grained naturally 
occurring motivational speech than current MI process tools allow. Further research is 
needed before any definitive claims can be made, however eliciting autonomous 
motivation speech may represent a direction for future research into the clinical 
application of MI.     
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Appendix 3 SMACS Coding Manual 
Self-determination theory & Medication Adherence Coding 
System 
The overall aim of this coding manual is to identify all references to the client’s 
reasons for adhering to the antiretroviral therapy medication. These reasons will be 
categorised according to two different types of motivation (autonomous  or 
controlled). The rest of the speech utterances are to be coded as non-motivation 
client speech.  
Notes to coder 
It is important to listen to the audio recording while coding the written transcript of 
the session. All transcripts will be separated or parsed (using parentheses) into 
individual segments of speech. The coder will assign one of three codes 
[autonomous motivation (AM), controlled motivation (CM), and non-motivational 
client speech (N)] to the client speech utterances only. The same utterance may 
never be given two different codes. Therapist speech is not assigned a code but 
often will serve to provide context for client speech (see coding examples given 
below). Reasons to adhere are time specific and only those related to current or very 
recent motivation to adhere are coded as being autonomous motivation or 
controlled motivation. All references to historical motivation is to be coded as non-
motivational client speech. 
Codes  
1. Autonomous Motivation (AM) 
Autonomous motivation is where behaviour is perceived as being chosen by oneself 
and the person believes that the behaviour is under their control.  It includes when 
the person states that the behaviour is important to achieve personally valued 
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outcomes. The person recognises and accepts the underlying value of the behaviour. 
Autonomous motivation also includes where the person identifies with the 
importance of a behaviour and this behaviour is in line with their core values and 
beliefs about the self. Carrying out the behaviour is seen to be consistent with other 
priorities in the person’s life and forms part of their identity. 
Examples of autonomous motivation in relation to antiretroviral medication 
adherence include: 
 
o Part of my identity  
T:  [ So you rely on yourself and not others. Ok.] [Now can you think about 
how adherence and taking your medications consistently is maybe related to 
being considerate or being independent or strong?]  
C: [Oh, I take my meds cause it’s just who I am.] (AM) 
T:  [Um-hmm.]  [So that’s just a core part of your personality?]  
C:  [Right.] (AM) 
 
 
o Important to me  
 
C. [It is important to me to adhere to my medication.] (AM) 
 
C. [I take my medication because I need to, it’s for me.] (AM) 
 
C. [I take my medication for myself, if I make a point of doing something I do 
it.](AM) 
 
 
o I want to be there for my children 
T: [A 10? Ok. So that’s a pretty high number, that’s like the highest on the, on 
the scale]  
C. [Yea, because I don’t wanna...wind up goin’...you know this is my last 
regimen…and uh…I have my son to think about] (AM) 
T: [Mhmm].  
C. [That’s my main priority]. (AM) 
 
 
o I value taking my medication 
C. [I take medication as I value the benefits I get from it.] (AM) 
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2. Controlled Motivation (CM) 
Controlled motivation is where the behaviour is compelled by the self or by others. 
The person engages in the behaviour to gain a reward, avoid punishment or avoid 
negative emotions. Controlled motivation can include rewards and punishments that 
are delivered by other people. For example, taking medication to receive recognition 
from a health professional (reward) or to avoid criticism from a loved one 
(punishment). It can also include financial and legal constraints or pressure from 
other people including society in general, for example, in cases where ART 
adherence is mandated by a medical practitioner or as part of a research trial.  
 Controlled motivation can also include where a person is motivated by some 
internalised self-esteem related judgement and in this case the behaviour is self-
imposed.  The person is seen as self-controlling by putting pressure on themselves to 
comply with the behaviour. They will feel guilt, anxiety or shame when they fail at 
the behaviour and will feel pride and increased self-worth when they are successful. 
Although the motivation is internally driven the causality is deemed to be external as 
it is not viewed as being part of the person’s self. 
Examples of controlled motivation in relation to antiretroviral medication adherence 
include: 
 
o My family make me take my medication 
T:  [on Saturday.] [So, tell me a little bit about what helped you take your 
medications on the days you took both doses, like Thursday, Friday, and 
Sunday?] 
C. [My dad and my son are staying on my butt about taking it.] (CM) 
T:  [Okay, so you had that, like reminder] 
C. [Yea. (laughing)] (CM) 
 
C. [I feel under pressure from my family to take my medication (CM) 
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o To prevent hospital admission 
T: [Well, umm, you mentioned that it’s very important for you to take your, 
your HIV medication.] [Can you tell me a little bit about why, why it’s 
important for you to take those?] 
C. [Hmm…good question.] (N)  [Well…I’ll turn out like a vulture, and end up in 
the hospital.] (CM) 
T: [Mmhmm.] 
C. [You know.] (N) 
T: [Ok.]  
C. [It’s the only way I’m gonna get better.] (CM) 
 
o Extending my life 
T.  [Ok. And what are the upsides of taking your ART meds?]  
C.  [Controlling this fabulous virus.  Um, ya know, again – Mortality is a reality 
for every single one of us.  Ya know, we’re dying…] (CM) 
T.  [Can’t get away from it.]  
C. [Exactly, from the moment of conception we’re dying. So, if I can delay 
that by, even just a little but, and those help me do it, by all means.] (CM) 
T.  [So positive for you is being able…taking your medication gives you sense 
of control…and you’re able to do that?]  
 
 
o I take my medication because my family will be sad if I get sick  
T: [Right. That’s great.] [Well you’ve already told me some of the real positive 
things, reasons why you want to take them. Obviously, which is to live and all 
the things you have to live for.] 
C. [Right.] (AM) 
T: [Yeah. Family and yourself.] 
C. [Right.] (AM) 
T: [I guess you have to be…] 
C. [Myself first.] (AM) 
T: [Right.] 
C. [Then my child. And then my lover.] (AM) 
T: [Right.] 
C. [And so on.] (N)   
T: [Well you can’t…yeah, if you’re not healthy you can’t really be around.] 
C. [Right. You can’t make, you know, can’t be around anybody else if they 
gonna be helping you.] (N) 
T: [Right, exactly.] 
C. [They’re gonna be sad because you’re sick.] (CM) 
T: [That’s right.] 
C. [That’s basically it.] (N)  
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o What others would think of me  
C. [I want my doctor to think I’m a good patient so I adhere to my ART] (CM) 
C. [I want others to see that I’m trying to take the medication.] (CM) 
 
o To make others happy 
C. [It makes my loved ones happy when I take my medication] (CM) 
 
o Otherwise I would think and feel bad about myself 
C. [I would feel like a failure if I didn’t adhere to my ART.] (CM) 
C. [I feel guilty if I don’t comply with my medication regime] (CM) 
C. [I feel ashamed when I miss a dose of my medication] (CM)  
 
o Taking my medication makes me feel better 
T: [Okay. So it’s important for you because that means that you feel better 
when you take your medicines.]  
C. [Uh-huh, Yeah.] (CM) 
 
o No choice 
C. [I take my medication because I have no other choice.] (CM) 
 
Differentiating Autonomous Motivation from Controlled Motivation 
At times autonomous motivation can be confused with controlled motivation. It is 
important to consider if there are any external rewards, punishments or avoidance 
that is keeping the behaviour going. If there are then the adherence reasons should 
be coded as controlled motivation.  Note if you are struggling to decide between 
autonomous motivation and controlled motivation it is most likely controlled 
motivation, therefore code it as such.  
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C: [I take my medication because I don’t want to end up in hospital again] (CM) 
C: [I look in the mirror and see that I’ve put on weight and that keeps me 
motivated to take my medication] (CM) 
C: [I would feel bad about myself if I didn’t adhere to my medication] (CM) 
 
 
Adherence & Health 
Where the person has indicated at some point during the transcript that their health 
is personally valued to them then any reasons for taking medication relating to 
health are coded as Autonomous Motivation for this person. If the person has not 
indicated that they value their health at any point in the transcript and an 
improvement in their health is presented as a description of the consequence of 
taking their medication, then it is coded as Controlled Motivation. 
 
 
T: [ I have this list of values here, um if you could pick out maybe two or three 
things that really stick out for you or values that you really hold dear, um 
then we can talk about that.]  
C 1: [Being healthy is one.] (N) 
… 
T: [Okay. Okay, now you mentioned being healthy, being a good parent, and 
being responsible were all values that were very important to you. Can you 
see how taking your HIV medications relates to the values that you 
mentioned? ] 
C 1: [ Well, taking HIV meds will probably make me healthier. ]  (AM) 
     ******************* 
 
 
T: [I have a list here. And if you wouldn’t mind if you could pick maybe two or 
three things on that list that you value and we can talk about that. ]   
C 2:  [Being strong, and being happy. ]  (N) 
… 
T: [Can you tell me a little bit about why, why it’s important for you to take 
those? ]   
C 2:  [ It’s the only way I’m gonna get better, taking the HIV meds is gonna 
improve my health so I’m not in the hospital or really sick or anything. Ok. ]  
(CM) 
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3. Non-motivational client speech (N) 
All client speech which cannot be coded as autonomous motivation or controlled 
motivation is coded as non-motivational client speech. This code will account for the 
vast majority of client speech. This category includes amotivational speech, which 
refers to the absence of any intention and thus motivation to engage in a behaviour.  
All speech relating to historical motivation is coded as non-motivational client 
speech.  
 
T:  [Okay.  So, why do you think for, for you though you decided that it’s very 
important for me to take my medications?]  
C. [Uh, cause, cause when I wasn’t taking it, I wasn’t feeling good at all and I 
was losing weight.] (N) 
 
